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Abstract 
Human embryonic stem cells (hESCs) have the unique ability to differentiate 
into all kinds of cells in our body, including cardiomyocytes. HESCs therefore 
represent a novel source of human cardiomyocytes for cell replacement therapy such 
as for the treatment of myocardial infarction (MI). However, under conventional 
protocol of hESC differentiation, a mixed population of heterogeneous cells is always 
present. Therefore, one of the aims of my project is to purify hESC-derived 
cardiomyocytes. 
HESCs are resistant to common gene manipulation methods such as 
transfection. To establish stable, genetically modified hESC line, lentiviral vector was 
employed as the gene delivery tool. A lentiviral vector whose GFP expression is 
driven under the control of cardiac specific promoter was made and used to transduce 
hESCs. Antibiotic selection was done to establish the cell line. After differentiation of 
the cell line, fluorescence activated cell sorting was performed to sort out green 
populations. However, quantitative PGR on sorted cells did not show up-regulated 
expression of cardiac specific genes in green populations (Vs that of non-green 
population). It is believed that fine-tuning of the experimental conditions is needed as 
discussed in the text. 
In addition, previous studies showed that infarcted hearts secrete a portfolio 
i 
of proinflammatory cytokines, it is therefore crucial to understand the effects of these 
cytokines on embryonic stem cell differentiation, as this will in turn affect the 
functional efficacy of cell replacement therapies. Therefore, in vitro study on the 
effects of several pro-inflammatory cytokines, namely interleukin (IL)-la, IL-lp, IL-6, 
IL-10, IL-18 and tumor necrosis factor-a on mESC differentiation was conducted. The 
results showed that different cytokines have differential effects on the mRNA and 
protein expressions of several cardiac specific genes. These findings were discussed 
in details in the discussion section of this thesis. Further works are deemed necessary 
to allow us to have a better understanding on the potential therapeutic uses of 
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Chapter 1 -Introduction 
Chapter 1 
Introduction 
1.1 Stem cells 
Stem cells are unspecialized cells which can develop into various cell types in the 
body. While they can be used to replenish or even heal damaged tissues and cells in 
the body, they serve as a sort of repair system for the body. When a stem cell divides, 
every single cell has the potential to either remain a stem cell or become another type 
of cell with a more specialized function, such as skin cell, red blood cell and nerve 
cells (see Fig. l . l )>^ 
“ ^ ^ y g o t e Totipotent cells Blastocyst Fetus Adult 
s—普 
• • Brain 
Inner Cell Mass ^ ^ ^ 
^^^J Liver 
一 Embryonic Stem Cells Heart � | 
Bone marrow 
• Others 
Pluripotent Stem Cells Multipotent Stem Cells 4 • 
^ Specialized CeUs ^ 
I r ^ ^ 
Hepatocytes Cardiomyocytes Hematopoietic Neurons 
r i a E H i 
Early Efficacy and Toxicity Screening Systems for Drug Development 
Fig. 1.1: Derivation of pluripotent and multipotent stem cells from zygote and their 
fates to be different specialized cells i 
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1.1.1 Adult stem cells 
Adult stem cells are undifferentiated cells found among differentiated cells in a tissue 
or organ. They are able to renew themselves and can differentiate to the major 
specialized cell types of the tissue or organ from where they are found. The main 
functions of adult stem cells are to maintain tissue homeostasis and in tissue repair.^ 
Adult stem cells have been propagated from bone marrow,^ brain,4 liver,^ skin^, 
adipose,7，8 skeletal muscle,9 and blood.川 In vitro, adult stem cells can differentiate 
into a broad range of cell types such as osteoblasts, adipocytes, endothelial cells, 
skeletal myocytes, glia, neurons, and cardiac myocytes. In addition, most adult stem 
cells can differentiate into other types of somatic cells.u 
1.1.2 Embryonic stem ceils (ESCs) 
ESCs were isolated from the inner cell mass of blastocyst stage embryos which are 
1) 
generally 5-7 days old.， They have two distinct characteristics which are 
pluripotency and self-renewal. Pluripotency refers to their ability to develop into any 
type of cells in the three germ layers, including gut epithelium of endoderm; cartilage, 
bone, smooth muscle, and striated muscle of mesoderm; and neural epithelium, 
embryonic ganglia, and stratified squamous epithelium of ectoderm. In regards of 
self-renewal, ESCs can be propagated indefinitely in the primitive undifferentiated 
state (see Fig. 
2 
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I 
Characteristics of Embryonic Stem Cells 
1. Origin: flH^flk 
Derived from pre-lmplantation Blastocyst 
or peri-implantation embryo ^ ^ ^ ^ ^ ^ 
《 9 Stem cell 
2. Self-Renewal: \ 
The cells can divide to make 泰i^^、 
copies of themselves for a i ^ ^ ^ 
prolonged period of time ^ 
without differentiating. X X r X 
C^ iC^ ) 参 � 
3. Pluripotency: 
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ceils from all three embryonic germ 
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in culture for a long time. / 
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Ectoderm Mesoderm Endoderm 
^ ^ ^ Neuron Blood cdis Liver c e l l ^ ' ^ 
Ectoderm gives rise to: Mesoderm gives rise to: Endoderm gives rise to: 
brain, spinal cord, nerve muscles- blood, blood vessels, the gut (pancreas, stomach, 
cells, hair, skin, teeth, connective tissues, and the liver, etc.), lungs, bladder. 
I sensory cells of eyes, ears heart. and germ cells (eggs or sperm) 
I nose, and mouth, and 
I pigment cells, 
i 
<0 
Figure 1.2.Characteristics of Embryonic Stem Cells. 
Fig. 1.2 Characteristics of ESCs, adopted from Regenerative Medicine 2006, National 
Institute of Health 
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While ESCs can proliferate unlimitedly and can differentiate into any type of cells, 
human embryonic stem cells are able to support basic research on the differentiation 
and function of human tissues, as a source material for drug testing and to provide 
unlimited amount of tissue for transplantation therapies for a wide range of 
degenerative diseases (see Fig. 1.3).16， 
In vivo, injection of ESCs into severe combined immunodeficient (SCID) mice gave 
12 
rise to teratomas which comprised of derivatives of many cell types. In vitro, when 
placed on non-adherent culture dishes, the cells form spherical structures termed 
embryoid bodies (EBs) and underwent spontaneous differentiation. Addition of 
growth factors during differentiation was shown to direct the commitment of cells 
towards different cell lineages”，18-24 
The Promise of Stem Cell Research 
f : . J ) 
MIL study cell 
ml Ik dtffere咖Ion ^ ^ 
\ • , 6 # 
i o I 
Toxicity testing < ; J 
Ectoderm : ‘ ’ Mesoderm -^^Emtodafm . i . A , , . ^^ 
I _ w ^ 够 
I Tissues/Cells lor Transplantation 
» _ _ “ . . 
Figure 1.3： The Promise of Stem Cell Research 
Fig. 1.3: The promise of stem cell research, adopted from Regenerative Medicine 
2006, National Institute of Health 
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1.1.3 Pros and cons of embryonic and adult stem cells 
The advantages of ESCs over adult stem cells include flexibility as ESCs are capable 
to derive into any cell type while adult stem cells have limited potential. Secondly, 
ESCs are immortal; therefore one ESC line can provide endless supply of cells. 
Nevertheless, ESCs are difficult to differentiate uniformly and homogenously into 
specific tissue. The mixture of cells is likely to be rejected after transplantation. 
Besides, while ESCs can divide indefinitely, tumors may form after injected into 
patients as cell replacement therapy. Lastly, peoples may argue that the use of ESCs 
maybe a destruction of developing human life. 
For the advantage of adult stem cells over ESCs, there are five major points. To begin 
with, adult stem cells are specialized cells, thus the inducement into target tissue will 
be simpler. On the other hand, recipients who receive their own stem cells will not 
experience immune rejection. Thirdly, they are relatively easy to obtain, such as from 
skin, muscle, marrow or even fat. Fourth, adult stem cells tend not to form tumors and 
to end with, no harm will be done to the donor. 
Unsurprisingly, adult stem cells got disadvantages. While they are harvested from the 
completely differentiated human body, it is sometimes difficult to obtain in large 
amount. Besides, they are finite and may not live as long as ESCs in culture. Lastly, 
they are more difficult to reprogram into different tissue types. 
5 
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1.1.4 Human embryonic stem cells (hESCs) 
HESCs were first isolated by James Thompson in 1998. At that time, human embryos 
leftover from in vitro fertilization (IVF) for clinical purposes were donated for 
1 ^ 
research after informed consent and the approval of the institutional review board. 
Five ESC lines originating from five independent embryos were derived. Three cell 
lines (HI, HI3 and HI4) shown a normal XY karyotype while the remaining two 
lines (H7 and H9) shown a normal XX karyotype. The derived undifferentiated cells 
are flat colonies with distinct border and had a high ratio of nucleus to cytoplasm and 
prominent nucleoli. 
HESCs were required to grow either on an embryonic fibroblast feeder layer with 
serum replacer supplemented with basic fibroblast growth factor (bFGF), or in 
feeder-free conditions using matrigel and specially formulated medium with high 
levels of growth factors such as bFGF and transforming growth factor p (TGFp).^^ 
The human ESC lines expressed pluripotent markers including stage-specific 
embryonic antigen (SSEA)-3, SSEA-4,TRA-l-60, TRA-1-81, Oct4 and Nanog. When 
they are coaxed to differentiation, a wide variety of cell types can be obtained, 
includes cardiomyocytes. The differentiated hESCs derived cardiomyocytes express 
cardiac markers such as cardiac troponin-I (c-Tnl) and a-myosin heavy chain 
(a-MHC). Moreover, they display similar physiological characteristics with their 
adult counterparts.26 Hence, it is believed that they can be used in cardiac cell 
replacement therapies and different in vitro applications including drug development 
and in vitro toxicology�’ Nonetheless, hESCs are resistant to common gene 
6 
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manipulation methods such as transfection. This makes genetic engineering of hESCs 
thorny and depreciates the research progress on hESCs. 
1.1.5 Mouse embryonic stem cells (mESCs) 
MESCs were first isolated as undifferentiated cells from the inner cell mass (ICM) of 
blastocyst-stage embryos in 1981?^' ^^  They have the capacity to differentiate into 
cells from the three germ layers in vitro. 
In order to keep mESCs undifferentiated and maintain a normal and stable karyotype 
with unlimited ability to self-renew, mESCs must be maintained in culture by 
co-culture with mitotically inactivated mouse embryonic fibroblast feeder layers or 
through the addition of leukemia inhibitory factor (LIF) to the culture media.^^'^^ 
The rtiESC lines expressed pluripotent markers including SSEA-1, membrane-bound 
receptors gpl30, transcriptional factors Oct4, and alkaline phosphatase.^^ 
1.1.6 Characteristics of ESC-derived cardiomyocytes 
There are many reports showing the successful derivation of ESC-derived 
cardiomyocytes (ESC-CMs)?^' ^^  Characterization of these ESC-CMs are usually 
done at molecular level, electrophysiological level and functional level. 
At molecular level, RT-PCR and immunostaining were done to check for the cardiac 
specific markers e x p r e s s i o n . � � ， 3 4 Examples of cardiac specific markers include 
7 
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transcription factors GATA4, Nkx2.5 and cardiac proteins a-MHC, c-Tnl, c-TnT, 
MLC-2a and MLC-2v. 
For electrophysiological level, whole cell patch clamp studies for the presence of 
cardiac-specific action potential, extracellular electrogram display of cardiac specific 
depolarization and repolarization processes and [Ca ]i transient measurement were 
done to examine the physiological properties of cardiomyocytic tissue which are 
differed from skeletal or smooth muscle. 
At functional level, ESC-CMs were injected into infarcted hearts of small animals, 
twelve-lead electrocardiography, echocardiography and histopathology were 
performed. By electrocardiography, disappearance of Q waves which reflect net 
reduction of myocardial necrosis was observed in ESC-CMs treated group but not in 
sham-treated group. By echocardiography, left ventricular ejection fraction improved 
from 47% back to 83% was measured. For histopathology, diminish of postinfarction 
left ventricular scar was determined. 
8 
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1.2 Cardiovascular Diseases (CVD) 
1.2.1 Causes and statistics of CVD 
Cardiovascular disease (CVD) is caused by disorders of heart and blood vessels. It 
includes coronary heart disease (see Fig. 1.4), cerebrovascular disease, hypertension, 
peripheral artery disease, rheumatic heart disease, congenital heart disease and heart � 
failure. The major risk factors are smoking, unhealthy life style and high fat diet.^^ 
Z H e a r t Attack 
Z b I o o c | c lot Artery 
Coronary arteries _ _ 
Healthy mus c l e 
Dying mus c l e 
Fig. 1.4: An overview of a heart and coronary artery showing damage caused by a 
heart attack. The cross-section of coronary artery shows a plaque buildup and a blood 
clot. 
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CVD is the number one cause of death globally and it is predicted that 20 million 
people will die from cardiovascular disease every year by 2015, mainly from heart 
attacks and strokes (see Fig. 1.5) (WHO, 
http://www.who.int/cardiovascular—diseases/en/). Heart attacks and strokes are 
mainly caused by the deposit of fat on the inner walls of blood vessels that supply 
blood to the heart or to the brain. This makes the blood vessels become narrower and 
less flexible and also known as hardening of the arteries or atherosclerosis (see Fig. 
1.4). 
Communicable diseases, 
_ __ maternal and perinatal 
C?n^e「+ Chronic conditions and fiutritlonal 
respiratory diseases 中 deficiencies 
Diabetes / 
22% \ / 肌 
/ \ Injuries 9% 
Cardiovascular diseases 30% ^^^^ chroi^ ic 
diseases 9% 
Fig. 1.5: Source: World Health Organization 
1.2.2 Current treatment for CVD 
Therapies for cardiovascular disease depend on the specific type of disease for each 
patient, but effective measure come first with preventive lifestyle to eliminate risk 
factors such as cholesterol for CVD. Preventive lifestyle includes smoking cessation 
1 0 
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and regular aerobic exercise complements with healthy eating habits. 
For medications, beta-blockers, blood pressure reducing drug, aspirin and 
cholesterol-lowering drug, statin, were used to attenuate the deterioration of cardiac 
function after myocardial infarction (MI). In some occasion, surgery like coronary 
angioplasty and coronary artery bypass grafting may be done to re-open, repair or 
replace damaged blood vessels. However, the above mentioned conventional 
therapies for MI attenuate disease progression without contributing significantly to 
repair. While cardiomyocytes are cells that retain limited regenerate capacity, once 
they are damaged or lost, there will be permanent lost of cardiac capacity. In this 
circumstance, whole heart transplant would help to restore cardiac functions. But due 
to limited supply of heart because of lack of donors, hESCs which have the capacity 
for de novo cardiogenesis would be a potential cell source for myocardial 
regeneration. ^^  
1.2.3 Current hurdles of putting hESC-derived CMs into clinical uses 
As mentioned above, ESCs can be the excellent cells source due to their self renewal 
and pluripotency. ESCs have unquestionable cardiogenic potential (please see section 
1.1.6 for details) and can therefore provide unlimited supply of cardiac cells for 
therapeutic purposes. Previous reports suggested that transplantation of hESC-CMs 
into infarcted heart improved cardiac functions compared to animals receiving 
non-cardiomyocyte derivatives. ， ，， Even so, there are important issues yet to be 
addressed before ESCs can be used for cell replacement therapy efficiently. Firstly, 
differentiated hESCs are in mixed cells population and among all, cardiomyocytes 
1 1 
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only contribute less than 1% of the whole cells population.^^ Therefore, the purity and 
yield of cardiomyocyte should be increased for therapeutic application. On the other 
hand, we need to take care of the problem of immune response as ESCs are not 
originated from patient bodies. While different maturity of cells also affects the cells 
behaviors and functions, we need to well study the characteristics of differentiated 
cells at different status. If cells did not terminally differentiate and got some 
proliferation ability, tumors may form if cells were injected for cell replacement 
therapy. 
1 2 
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1.3 Myosin light chain 2v 
Myosin is a multimeric contractile protein which composed of two heavy chain 
subunits, two essential or alkali light chains and two phosphorylated regulatory light 
chains. Myosin heavy chains and myosin light chains exist in a variety of isoforms 
and each expressed differently in various tissues and at different developmental stages 
within the same tissue. ^。，斗！ 
The cardiac myosin light chain can be divided into two categories: the alkali light 
chains (MLC-1, non-phosphorylatable), and the regulatory light chains (MLC-2, 
phosphorylatable). Phosphorylation of the regulatory MLC-2 by myosin light chain 
kinase increases force and accelerates the rate of force development in m y o c a r d i u n / � 
but slows relaxation.43 Previous work even concluded that the ventricular isoform of 
MLC-2, MLC-2v, is required for normal myofibrillogenesis in mouse ventricle.44 
In fact, MLC-2v is a well known cardiac marker which exclusively expresses in the 
v e n t r i c l e . 4 5 Therefore, the MLC-2v promoter was employed in this study for the drive 
of GFP for labeling cardiomyocytes that consist of the essential transcriptional factors 
for gene transcription downstream. The chosen human MLC-2v promoter includes a 
fragment which is homologous to a 250bp fragment in the rat MLC-2 promoter， 
which was proved to be sufficient for cardiac specific expression.46，47 
1 3 
Chapter 1 -Introduction 
1.4 Genetic-engineering of hESCs and their cardiac derivatives by 
lentiviral-mediated gene transfer 
Lentivirus (LV) is a gene delivery tool of an expression cassette which made up of 
one or more genes and their regulatory sequences to target cells. The transgene 
expression is stable in both dividing and non-dividing cells, either in vitro or in 
several organs in vivo.^^'^'^ 
Lentivector particles are generated by co-expressing the virion packaging elements 
and the vector genome in a cell used as producer, for instance a 293 or 293T human 
embryonic kidney cell. In the case of HIV-1-based vectors, the core and enzymatic 
components of the virion come from HIV-1, while the envelope is derived from a 
heterologous virus, most often vesicular stomatitis virus (VSV) due to the high 
stability and broad tropism of its G protein.51 
There are many advantages in using lentiviral vectors for gene targeting when 
compared with the use of other retroviral vectors. First of all, LVs can transduce both 
mitotically active and inactive cells such as h E S C s . N e x t , transgenes introduced 
with the LV backbone that integrated into the host genome are more resistant to 
transcriptional s i l e n c i n g . 5 4 In addition, the self-inactivating (SIN) LVs with 
permanently disable viral promoter within the viral long-terminal repeat (LTR) after 
integration enable transgene expression to be solely controlled by an internally built 
promoter. Besides, LVs can better accommodate multiple promoters, which are either 
ubiquitous or cell-specific.^^ Lastly, while the lentiviral vector will stably integrate 
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into the chromosomes of their targets, the gene expression will be permanent. 5i，54 
1.5 Cytokines secretion during MI 
Previous studies shown that myocardial infarcted hearts secrete a portfolio of 
inflammatory cytokines, well known examples as Tumor Necrosis Factora (TNF-a), 
56-58 Interleukin(IL)-la,59 IL-ip^,�？ il-6,56.60 iL-lO^^and IL-18.^' Although there are 
different pathways which can put a single cytokine to the beneficial 
immunoregulatory and the detrimental pathophysiological sides in cardiovascular 
disease, it is crucial to understand the effects of these cytokines on the differentiation 
of ESCs, as this will affect the functional efficacy of cell replacement therapies. 
I L - l a 
IL-la is an acidic 17kDa protein encoded by the gene which has 10,206 bp with 7 
exons and 6 i n t r o n s ? It is synthesized by a variety of cell types including activated 
macrophages, keratinocytes, stimulated B lymphocytes, and fibroblasts.^^ There are 
two types of receptor for IL-la, namely interleukin 1 receptor type 1 and 2 (IL-lRl 
and IL1-R2) or cluster of differentiation (CD) 121a and 121b. It is a potent mediator 
of inflammation and immunity. After MI, gene expression of IL-la was increased up 
to 2 months compared with normal control.^^ Experimental data demonstrated that 
IL-la is involved in apoptosis and is released as a consequence of cell injury.^^ 
IL- lp 
IL-lp is a 18kDa polypeptide synthesized by a variety of cell types including 
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activated macrophages, keratinocytes, stimulated B lymphocytes, and fibroblasts.^^ 
It shares the same IL-lRl and IL-1R2 receptors with IL-la. IL-ip has pleiotropic 
proinflammatory effects.^^ In mouse infarcts after 6 hours of reperfusion, IL-lp 
mRNA expression was markedly increased, i.e. >20 folds, compared with 
sham-operated controls，？ 
IL-6 
IL-6 is a 185 amino acid polypeptide.^^ It is produced not only by immune related 
cells such as monocytes and macrophages,^^ it is also produced by cardiovascular 
components like endothelial cel ls?�and vascular smooth muscle cells.?' IL-6 is a 
pleiotropic cytokine with a variety of biological activities; for instance it can 
Stimulate B-cell differentiation, activate thymocytes and T-cells for differentiation, 
activate m a c r o p h a g e s , ？ 斗 stimulate hepatocytes to produce acute-phase proteins,^^ and 
activate natural killer (NK) cells. IL-6 signals through a cell-surface class I cytokine 
receptor complex consisting of the ligand-binding IL-6Ra chain (CD 126), and the 
signal-transducing component gpl30. It has both pro-inflammatory and 
anti-inflammatory properties. Expression of IL-6 mRNA was about 7 folds higher in 
neointimas of mice subjected to both acute MI and arterial injury than those of mice 
subjected to arterial injury alone7^ Convincing data also proved that IL-6 family 
plays a central role in the pathophysiology of c a r d i o v a s c u l a r d i s e a s e s ， 。 
IL-10 
IL-10 is a polypeptide chain containing 161 amino acids and having a molecular mass 
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of 19kDa. It is an important immunomodulatory cytokine produced by Th2-type T 
cells, B cells, monocytes, and macrophages. The receptors for the IL-10 family are all 
members of the class II cytokine receptor family (CRF2). All functional receptors 
are heterodimers composed of an alpha or type 1 (Rl) chain and beta or type 2 (R2) 
chain. It reduces antigen presentation and inhibits T cell activation^^' ^^  Previous 
study has shown that IL-10 is crucial for atherosclerotic plaque stability, by blocking 
the synthesis of proinflammatory cytokines. ’ In recent study, it was found that the 
mean serum level of IL-10 was significantly higher in acute myocardial infarcted 
Q 2 
patients than control patients. It was promoted that the serum IL-10 level can be a 
major independent predictor of 30-day mortality and should be used for early risk 
Stratification following acute ML 
IL-18 
IL-18 is a member of the IL-1 family. It was identified as an 
interferon-gamma-inducing f a c t o I t is produced as a 24 kDa inactive precursor 
lacking a signal peptide in macrophages, dendritic c e l l s , Kupffer cells,^^ 
n n o o OQ Qrj 
keratinocytes, osteoblasts, adrenal cortex cells, intestinal epithelial cells, 
microglial cells^^ and synovial fibroblasts.^^ Biologically active, mature 18 kDa 
moiety will generate only after cleavage by the endoprotease IL-lp-converting 
e n z y m e . 9 3 The IL-18 receptor (IL-18R) belongs to the immunoglobulin superfamily 
and presents as a heteromeric complex comprised of alpha- and b e t a - c h a i n s ， ， 9 5 it 
was demonstrated that IL-18 is a pleiotropic proinflammatory cytokine acting in both 
acquired and innate i m m u n i t y , 9 6 and plays a crucial role in the inflammatory 
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cascade.93 ^^ acute MI patients, the plasma level of IL-18 was significantly higher 
than in control subjects.^^ In 2001, it was found that IL-18 was highly expressed in 
the atherosclerotic plaques compared to normal control arteries and was localized 
mainly in plaque macrophages. Besides, it was suggested that IL-18 plays a major 
role in atherosclerotic plaque destabilization leading to acute ischemic syndromes.^^ 
TNF-a 
TNF-a is primarily produced as a 212 amino acid-long type II transmembrane protein 
go 
weighted 26kDa and arranged in stable homotrimers. It is a proinflammatory 
cytokine with pleiotropic f u n c t i o n s ， I n an immune response, TNF-a production is 
enhanced in T cells and cells of the monocyte-macrophage l ineage . • Opposing 
effects of TNF-a were also observed such as the leading of myocyte apoptosis and 
preservation. These are achieved through two different TNF surface receptors 
(TNF-Rl and raised concentration of TNF-a has been reported in 
patients with acute and chronic heart f a i l u r e . � � i t is also reported that TNF-a 
can depress myocardial contractility, alter muscle membrane potential and lower 
blood pressure.iG4，io5 
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1.6 Aims of the project 
The first aim of the current study was to purify hESC-derived cardiomyocytes using 
genetic approach. Cardiac derivatives of hESCs were genetically labeled with green 
fluorescence protein whose expression was controlled under MLC-2v promoter, a 
cardiac-specific promoter, by lentivirus-mediated gene transfer. Differentiation of this 
transgenic hESC line followed by fluorescence-activated cell sorting techniques could 
then be done to sort out GFP positive cells for further analysis. 
The second aim of the present study was to examine the in vitro effects of different 
proinflammatory cytokines that are released during MI on the differentiation of 
ESC-derived cardiomyocytes. 
1.7 Significances of the project 
The present report may generate purified cardiomyocyte population for future 
myocardial cell replacement therapy. Additionally, this may also serve as a platform 
for solving other bottleneck issues for putting ESCs in practical therapeutic uses. For 
instance, the hESC line established may act as a reference in studies examining the 
effects of different interventions on cardiac differentiation which in turn may increase 
the yield of cardiomyocytes derived from ESC differentiation. For the 
pro-inflammatory cytokine effect on ESC differentiation, some insights may be 
obtained in the suitability of cardiac progenitor cells for transplantation and the time 
and place for cell injection, i.e. in the presence or absence of the secreted 
pro-inflammatory cytokines. 
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Chapter 2 
Materials and Methods 
2.1 Subcloning 
2.1.1 Amplification ofMLC-2v 
Pairs of primers were designed flanking the full length of human ventricular myosin 
light chain 2 (MLC-2v) promoter sequence from vector pKM2L-phMLC2V (RIKEN 
BRC DNA Bank, RDB No. 5900) with the addition of Pad restriction site and Kpnl 
restriction site to the 5' and 3' primer respectively and a clamp sequence (5' 
ACTGAC 3') to both forward and reverse primers to facilitate restriction digestion, as 
listed in Table 1. 
Polymerase chain reaction (PGR) was performed in a 50 |il mixture with 0.3 mM each 
of the designed primers, IX Pjx amplification buffer, IX enhancer buffer, 0.3 mM 
dNTP mixture, 1 mM MgSOzt, 100 ng template DNA and 1 unit of Platinum Pfic DNA 
polymerase. PGR reaction was performed using PTC-200 DNA Engine (Petlier 
Thermal Controller) by denaturing at 94 °C for 2 minutes, followed by 35 cycles of 
amplification at 94 for 15 seconds, 60 for 30 seconds, 68 for 2 minutes and 
30 seconds，with a final extension at 68 for 30 seconds. 
The PGR product was analyzed on a 1% TAE agarose (Invitrogen) gel with 0.7 |Lig/ml 
ethidium bromide (Invitrogen). The gel was visualized and photographed under ultra 
violet light, using a UVitec DNA gel machine. 
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2.1.2 Purification of DNA products 
Electrophoresis was used to separate the PCR products according to the size of DNA. 
Desired PCR products were visualized on a Transilluminator and then excised 
out and weighted. Purification of PCR product from the gel was performed using 
QIAquick DNA Extraction Kit (QIAGEN). The excised gels were dissolved in 3 gel 
weight/volumes (g/rtiL) of QC buffer at 55 "^C for 15 minutes, with occasional shaking. 
One gel weight/volume of isopropanol was added to the dissolved mixture to 
maximize the yield of DNA. The mixture was then flown through QIAquick spin 
column connected to a 2 ml collection tube. The column was then subjected to 
centrifugation at 13,000 rpm for 1 minute. The flow through was discarded and the 
DNA bound to the column membrane was washed once with 700 |il PE buffer. Again, 
the column was centrifuged at 13,000 rpm for 1 minute and the flow through was 
disposed. The membrane was then air-dried for 3 minutes to remove any residual 
ethanol in the buffer. The membrane bound DNA was finally dissolved in 50 fil of 65 
°C sterile nano pure water for 2 minutes at room temperature and eluted by 
centrifugation at 13,000 rpm for 2 minutes. 
2.1.3 Restriction enzyme digestion 
Restriction enzyme digestion of the purified PCR product and the target vector 
DuetO 11 were performed in a 20 |LI1 reaction mixture containing 10 units of Pad, 10 
units of Kpnl IX NEBl buffer and sterile nano pure water. The reaction mixtures 
were incubated at 37 °C for 3 hours for restriction digestion followed by heat 
inactivation at 65 for 20 minutes. The digestion products were analyzed on a 1% 
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TAE agarose gel and the target bands were excised and purified as described in 
section 2.1.2. 
2.1.4 Ligation of MLC-2v promoter with DuetOll vector 
Ligation of the Pad and Kpnl digested and purified MLC-2v fragment and DuetOll 
plasmid was performed in a 20 jil reaction mixture containing IX ligation buffer, 10 
ng Pad/ Kpnl digested DuetOll, 30 ng Pad/ Kpnl digested and purified MLC-2v 
fragment, 400 units of T4 DNA ligase (NEB) and sterile nano pure water. A control 
reaction was included in parallel by replacing DNA insert with water. The reaction 
mixture was incubated at 16°C for 16 hours for ligation. 
2.1.5 Transformation of ligation product into competent cells 
The frozen competent cells E. coli strain DH5a cells were thawed on ice for 10 
minutes. Ligation mixture was then mixed with 200 )LI1 competent cells and incubated 
on ice for 20 minutes. The cells and DNA mixture was then heat shocked at 42 °C for 
90 seconds followed by a chill on ice for 3 minutes. Then, to the cells mixture, 800 )LI1 
LB medium was added and cells were incubated at 37 °C for 1 hour under shaking at 
250 rpm. After incubation, bacterial cells were subjected to centrifugation at 6,000 
rpm for 1 minute. The cells pellet was resuspended in 150 |il LB medium and all of 
the cell suspension was spread onto LB agar plate containing ampicillin (50)Lig/ml). 
The plate was incubated at 37 for 16 hours in an inverted position. 
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2.1.6 PCR confirmation of successful ligation 
Single colonies of the transformants were picked up from the LB-ampicillin plate and 
streaked onto a fresh LB-ampicillin plate grid to keep the back-up and assign a 
number to each colony which was then incubated at 37 °C for 16 hours. The pipette 
tip with each single colony streaked on LB-ampicillin plate grid was then shaked in a 
0.2 ml tube containing PCR master mix to release any residual bacterial cells. The 
PCR master mix for each reaction was in 24 |LI1 and includes 2.5 units Ducan Taq 
polymerase, IX MgCh free PCR buffer, 200 nM dNTP mixture, 1.5mM MgCb, 
200nM of gene specific forward primer and vector specific reverse primer as shown 
in Table 2 and sterile nano pure water. The reaction was performed on a PTC-200 
DNA Engine (Petlier Thermal Controller) by denaturing at 94 °C for 3 minutes 
followed by 35 cycles of amplification at 94 °C for 45 seconds, 55 for 30 seconds 
72 for 2 minutes and 30 seconds and final extension at 72 for 10 minutes. The 
PCR products were analyzed on a 1% TAE agarose gel. 
2.1.7 Small scale preparation of bacterial plasmid DNA 
The clones that gave desirable PCR product were inoculated in 5 ml LB medium 
containing 50 |ag/ml ampicillin and incubated at 37 250 rpm for 16 hours. The 
overnight culture was harvested by centrifugation at 6,000 rpm for 5 minutes. After 
the supernatant was discarded, the small scale preparation of bacterial plasmid DNA 
was done by QIAprep Miniprep Kit (Qiagen). The cell pellet was resuspended in 250 
|al Buffer PI. Then, 250 |LI1 Buffer P2 was added to cell suspension and stood for 3 
minutes to lyse the cells. When the lysis reaction completed, 350 |il Buffer N3 was 
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added to neutralize the lysis buffer and then cells were subjected to centrifugation at 
13,000 rpm for 10 minutes. The supernatant was then applied to the QIAprep spin 
column and centrifuged for 1 minute. The flow through was discarded and the 
QIAprep spin column was washed by the addition of 0.5 ml Buffer PB followed by 
centrifugation at 13,000 rpm for 1 minute. Again, the flow through was discarded and 
the QIAprep spin column was washed once a time by addition of 0.75 ml Buffer PE 
followed by centrifugation at 13,000 rpm for 1 minute. An additional centrifugation at 
13,000 rpm for 1 minute was performed to remove any residual wash buffer. At last, 
QIAprep spin column was placed in a clean 1.5 ml tube and 50 |LI1 Buffer EB was 
added to the centre of the column. The column was let stood for 1 minute to allow 
DNA bound to the column to dissolve in the Buffer EB and DNA was then eluted by 
centrifugation at 13,000 rpm for 1 minute. 
2.1.8 Restriction enzyme digestions to reconfirm positive clones 
Restriction enzyme digestions to reconfirm positive clones of resultant lentiviral 
vector Duet011-MLC2v with MM and Apal were performed separately in 20 [i\ 
reaction mixtures. For Mlul digestion, 1 |Lig lentiviral vector, 5 units of MM, 2X 
One-phor-all buffer supplemented with sterile nano pure water were added. For Apal 
digestion, 1 [ig lentiviral vector, 25 units of Apal, IX NEB4 buffer and sterile nano 
pure water were added. The reaction mixtures were incubated at 37 °C for 3 hours for 
restriction digestion followed by heat inactivation at 65 °C for 20 minutes. The 
digestion products were analyzed on a 1% TAE agarose gel and the target bands were 
visualized on a 2UV™ Transilluminator. 
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2.1.9 DNA sequencing of the cloned plasmid DNA 
DNA sequencing for the cloned expression vector was performed by the commercial 
sequencing service TechDragon Company with seven designated primers listed in 
Table 3 which is either specific to the vector flanking our MLC-2v target gene or 
specific to the target gene itself. 
2.1.10 Large scale preparation of target recombinant expression vector 
After verification of the insert gene by DNA sequencing, clones with target inserts 
were inoculated into 150 ml LB medium containing ampicillin (50 |Lig/ml). The 
culture was incubated at 37 250 rpm for 16 hours. Next day, the bacterial cells 
were harvested by centrifugation at 6,000 x g at 4 °C for 15 minutes. After the 
supernatant was removed, the large scale preparation of confirmed bacterial plasmid 
DNA was done by QIAprep Midiprep Kit (Qiagen). The bacterial pellet was 
resuspended in 6 ml Buffer PI. Subsequently, 6 ml of Buffer P2 was added, mixed by 
vigorously inverting the sealed tubes 4-6 times and incubated for 3 minutes to lyse the 
cells. The cell lysate appeared viscous and was neutralized by 6 ml chilled Buffer P3. 
The lysate was then poured into the barrel of a QIAfilter Cartridge and incubated at 
room temperature for 10 minutes. The cap from the QIAfilter outlet nozzle was then 
removed and a plunger was gently inserted into the QIAfilter Cartridge to filter the 
cell lysate into a previously Buffer QBT equilibrated HiSpeed Tip. The clear lysate 
was allowed to enter the resin by gravity flow. When all lysate was flown through, the 
HiSpeed Tip was washed with 20 ml Buffer QC and DNA was eluted with 5 ml 
Buffer QF. The DNA eluted was then precipitated by mixing with 3.5 ml room 
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temperature isopropanol and incubated at room temperature for 5 minutes. The 
precipitated DNA was then passed through a QIAprecipitator under constant pressure 
and washed with 2 ml 70% ethanol. Finally, the DNA was eluted by 1ml Buffer TE. 
2.2 Mouse embryonic fibroblast (MEF) culture 
2.2.1 Derivation of MEF 
Neck dislodgement was performed on CF-1 or CD-I strain mice at 13-14 gestation to 
sacrifice mice. After the mouse abdomen was saturated with alcohol, the mouse was 
placed in a sterile primary culture hood with mouse belly up on an absorbant paper. 
Using sterilized instruments, skin was cut back and thus exposed the peritoneum. 
Instruments were resterilized by alcohol bath and Bunsen burner. Then, peritoneal 
wall was cut opened and uterine horns exposed. The whole uterine horns were 
removed and placed into a sterile petri dish where it was washed three times with 
10ml PBS. Subsequently, embryonic sacs were cut opened with watchmaker's forceps 
and scissors to release embryos. Released embryos were transferred to a new Petri 
dish where they were washed three times with 10 ml PBS. The number of embryos 
was counted and recorded. In the Petri dish containing PBS, visceral tissue which is 
in darker color was separated from the embryos. Cleared embryos were put into a 
fresh plate while visceral tissue was left behind. Again, the embryos were washed 
three times with 10 ml PBS. After excess PBS was removed with serological pipette, 
the embryos tissue was minced with curved dissecting scissors for approximately 
5-10 minutes into grain sized pieces. After that, 2ml trypsin was added and tissue was 
minced for additional few minutes until pieces are further reduced in size. Next, 5 ml 
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trypsin was added and the cells were vigorously pipetted up and down. Afterwards, 
the dish was placed into 37 incubator for 30 minutes. 
After the incubation was finished, the cells were pipetted vigorously up and down 
until it has a sludgy consistency. At this time, MEF culture media was added and the 
mixture can be distribute to T75 culture flasks and incubate at 37 overnight. The 
number of T75 flasks required equals to the number of embryos recovered divided by 
three. 
Next day, the primary cultures were viewed under microscope to determine the 
confluency of cell layer covering the flask surface. While the flasks were over 90% 
confluent, the cells were harvested. For stock keeping, cells were frozen in 10% 
DMSO/ DMEM medium at -80 overnight and transferred to liquid nitrogen for 
long term storage. 
2.2.2 MEF culture 
To thaw PO MEF derived from CF-1 or CD-I strain mice at 13-14 days gestation, a 
frozen stock vial was removed from liquid nitrogen. It was rolled between hands for 
about 10-15 seconds to remove frost. Then, the vial was immersed in a 37 water 
bath and swirled gently with the cap did not submerge. When only an ice crystal 
remains, the vial was taken out from the water bath and sprayed with 70% ethanol to 
reduce microorganisms from the water bath. Cells were transferred into a 50ml falcon 
with 1ml pipette. Immediately after, 4ml MEF culture media was added to cells to 
dilute the DMSO in the cryopreservation media. MEF culture media was added 
drop-wise to cells in falcon which kept shaking to avoid osmotic shock to cells. 
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Afterwards, cells were centrifuge at 200 x g, 4 for 5 minutes to remove 
cryoprotectant from cell culture. After supernatant was aspirated, the small cell pellet 
was reconstituted in 10 ml MEF culture media. Finally, the cells suspension was 
transferred to T75 flask and incubated at ？with 5% CO2 supply. Cell density was 
monitored daily and cells were passed at 1:3 or 1:4 ratio weekly to passage 4. 
2.2.3 Irradiation of MEF 
To harvest cells, MEF media was aspirated from the T75 flask while the cells 
monolayer remained attached to the flask surface. The flask surface was washed with 
5 ml PBS. After PBS was aspirated, 4ml trypsin- EDTA solution was added and the 
cells were incubated at 37 for 3-5 minutes. Cells were then dislodged from the 
flask surface by slapping the side of the flask with the heel of hand 3-5 times. 
Complete dislodgement of cells was checked under microscope. The flask was then 
put back into sterile tissue culture hood and 5 ml MEF culture media was added to 
inhibit trypsin reaction. A cell suspension was formed by mixing the dislodged cells 
and MEF culture media with a 10 ml serological pipet and all cells were then pooled 
into a 50ml falcon. Inhibited trypsin solution was removed by centrifugation at 200 x 
g, 4°C for 5 minutes. Next, cell suspension was vigorously pipetted to break all cell 
aggregates and cell count was performed. Cells required to plate for use was 
reconstituted to 20ml cell suspension and irradiated by gamma irradiation at 
7000-8000 rads. Irradiated cells were transferred in ice and centrifuge at 200 x g, 4°C 
for 5 minutes. As supernatant removed, cell pellet was resuspended at around one 
million cells per ml in MEF culture media. Cell number was counted again and cell 
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suspension was further diluted to required concentration, i.e. 1.4 X 10^ cells per ml. 2 
ml of cell suspension were placed on gelatin-coated 6-well dishes after excess gelatin 
was removed and incubated in incubator at 37 with 5% CO2 supply to allow cells 
to attach overnight. 
2.3 Human embryonic stem cells (hESCs) culture 
2.3.1 Thawing and plating hESCs 
A vial of hESCs HI (WiCell) was removed from the liquid nitrogen. It was rolled 
between hands for about 10-15 seconds to remove frost. Then, the vial was immersed 
in a 37 water bath and swirled gently with the cap did not submerge. When only an 
ice crystal remains, the vial was taken out from the water bath and sprayed with 70% 
ethanol to reduce microorganisms from the water bath. Cells were transferred into a 
50 ml falcon with 1ml pipette in a sterile culture hood. Immediately after, 4 ml hESC 
culture media was added drop-wise to cells to dilute the DMSO in the 
cryopreservation media while the falcon was kept shaking to avoid osmotic shock to 
cells. Afterwards, cells were centrifuged at 200 x g, 4 for 5 minutes to remove 
cryoprotectant from cell culture. After supernatant aspirated, the small cell pellet was 
reconstituted in 2.5 ml hESC culture media. Finally, the cells suspension was added 
into one well of a 6-well tissue culture plate containing the irradiated CF-1 strain 
MEF feeder layer. Plate was incubated at 37 with 5% CO2 supply. HESC culture 
media was refreshed daily and cells were split weekly. 
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2.3.2 Splitting hESCs 
hESC culture plate was removed from incubator and spent media was aspirated. 1ml 
of collagenase solution was added to each well of the six-well plate. The plate was 
then incubated at 37 5% CO2 for 5 minutes or until perimeter of colonies appear 
folded back. With a cell scraper, cells were scrapped off of the plate. The collagenase 
solution was pipetted up and down slowly to wash all cells off the surface. After all 
hESCs were removed from the surface, the cell suspension was pooled into a sterile 
50 ml conical tube and further pipetted up and down a few times to break-up cell 
colonies. Each well was washed with 1ml hESC media and the wash was transferred 
to the 50 ml conical tube. Broken cell colonies were then pelleted by centrifugation at 
200 X g for 5 minutes at 4 °C. The supernatant was aspirated and cell pellet was 
washed with 5 ml hESC media. Once again, cells were pelleted by centrifugation at 
200 X g for 5 minutes at 4 While hESCs were centrifuging, MEF media was 
aspirated from a fresh feeder plate. About 1 ml PBS was used to wash each well of 
the 6-well feeder plate to clear the serum. However, PBS cannot be left on fibroblasts 
for more than 5-10 minutes. When supernatant was aspirated from hESC pellet, cell 
pellet was reconstituted with a sufficient volume of media to the 50 ml conical tube to 
ensure a total of 2.5 ml media per well. Cell suspension was added slowly to each 
well of the 6-well plate after PBS was aspirated. The plating of hESCs was finished 
and the plate was returned to the incubator. The plate was moved in several quick, 
short, back-and-forth and side-to-side motions to further disperse cells across the 
surface of the wells. The cells were incubated overnight to allow small colonies to 
attach. Cell culture media was refreshed daily the next day onwards. 
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2.3.3 Culture maintainence, selection and colony removal 
a) Distinguish differentiated and undifferentiated cells and colonies 
Undifferentiated colonies were compacted with single hESCs with sharp edges. 
Differentiated colonies were recognized by several characteristics including large in 
size, merging with others, and dense and phase-bright centers compared to their 
edges. 
b) Remove differentiated cells by "Picking to Remove" 
When there are mostly undifferentiated colonies on the plate with only a few 
differentiated single cells and colonies, the differentiated cells were marked under 
microscope and removed by pipette tip in culture hood. The undifferentiated colonies 
were kept until they are ready for passage. 
c) Remove undifferentiated cells by "Picking to Keep" 
When there are only a few undifferentiated colonies on the plate with a large number 
of differentiated cells and colonies, the undifferentiated colonies were picked, plated 
and propagated. The differentiated cells were on the other hand, left on plate and 
discarded. 
2.3.4 Freezing hESCs 
hESC culture plate was removed from incubator and spent media was aspirated. 1ml 
of collagenase solution was added to each well of the six-well plate. The plate was 
then incubated at 37 5% CO2 for 5 minutes or until perimeter of colonies appear 
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folded back. With a cell scraper, cells were scrapped off from the plate. Extra care 
was paid to break up cell aggregates as little as possible while cells will recover more 
efficiently in large aggregates. The collagenase solution was pipetted up and down 
slowly to wash all cells off the surface. After all hESCs are removed from the surface, 
the cell suspension was pooled into a sterile 50 ml conical tube. Each well was 
washed with 1 ml hESC media and the wash was transferred to the rest of the cells in 
the 50ml conical tube. Cells were then pelleted by centrifugation at 200 x g for 5 
minutes at 4°C. The supernatant was aspirated and cell pellet was washed again with 
5 ml hESC media. Usually, this was two to three gentle pipeting motions to wash 
pellet as breaking up of cell aggregates should be avoided. Once again, cells were 
pelleted by centrifugation at 200 x g for 5 minutes at 4 °C. After supernatant was 
aspirated from hESC pellet, cells pellet was reconstituted in a volume of hESC media 
that is equivalent to half the final volume of the cell suspension. Next, an equal 
volume of cryopreservation media, 20% DMSO in normal medium, was added 
drop-wise and slowly to mixed with the cells. 1ml of the mixture was added to each 
cry0vial and the cryovials were placed in isopropanol freezing container and were 
frozen overnight at -70 In the following day, the vials were transferred to liquid 
nitrogen for long term storage. 
2.3.5 Differentiation of hESCs 
HESC culture plate was removed from incubator and spent media was aspirated. 1ml 
of collagenase solution was added to each well of the six-well plate. The plate was 
then incubated at 37 5% CO2 for 5 minutes or until perimeter of colonies appear 
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folded back. With a cell scraper, cells were scrapped off from the plate. Extra 
carefulness was paid to break up cell aggregates as little as possible while cell 
colonies can form embryoid bodies easier as a whole. The collagenase solution was 
pipetted up and down slowly to wash all cells off the surface. After all hESCs are 
removed from the surface, the cell suspension was pooled into a sterile 50 ml conical 
tube. Each well was washed with 1 ml hESC media and the wash was transferred to 
the rest of the cells in the 50 ml conical tube. Cells were then pelleted by 
centrifugation at 200 x g for 5 minutes at 4°C. The supernatant was aspirated and cell 
pellet was resuspended with 5 ml hESC differentiation medium. To proceed, cells 
were centrifuged again at 200 x g for 5 minutes at 4 After the supernatant was 
discarded, cells were resuspended with 15 ml differentiation medium and transferred 
to 100 mm low attachment Petri dish. Remaining cells in the 50 ml falcon were 
washed out by an extra 5ml differentiation medium and transferred to the 
corresponding low attachment dish. Cells suspension was incubated at 37 with 5% 
CO2 supply until day 7 for attachment. Cells suspension medium was changed every 
two days. 
Embryoid bodies (EBs) in suspension was pipetted into 50 ml falcon and let stand at 
room temperature for about 1 minute. Then about 2ml of the upper portion medium 
was pipetted back to wash remaining EBs in the Petri dish. When all cells were 
transferred to corresponding 50ml falcon, the falcon was let stand at room 
temperature for 10-15 minutes to allow EBs to sink to the bottom of the falcon. Spent 
medium was then removed until around 5 ml left. 10 ml fresh medium was then 
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added to resuspend sank EBs and seed them back to the original 100mm low 
attachment Petri dish. An extra 5ml differentiation medium was used to wash any 
remaining EBs left in falcon back to the Petri dish. The EBs in suspension were then 
put back to incubator at 37 °C with 5% CO2 supply. 
At differentiation day 7, all EBs were collected by the same method as medium 
changing for differentiating EBs in suspension. However, EBs in fresh medium was 
placed on 0.1% gelatin coated 6-well plate rather than 100mm low attachment dish. 
The next day, differentiation day 7+1, all EBs were attached and percentage of 
beating was begun to count. 
2.3.6 HESC culture on feeder free system, itiTeSR^^l 
a) Preparation of inTeSR™l 
Frozen mTeSR^l 5X supplement (Catalog #05852) was thawed at room temperature 
(15-25 °C) or overnight at 2-8 The entire 100 ml thawed 5X supplement was then 
added to 400ml basal medium for a total volume of 500 ml. The complete mTeSR^l 
was mixed well and stored as 50 ml aliquots. The aliquots were stable when stored at 
2-8 °C for up to 2 weeks or were stable when frozen at -20 for up to 6 months. 
b) Preparation of BD Matrigel™ hESC-qualified matrix aliquots 
BD Matrigel™ hESC-qualified Matrix (BD Catalog #354277) was thawed on ice or 
at 2-8 overnight. Sterile 0.5 ml vials were chilled on ice. Once chilled, the 
Matrigel™ was dispensed into the vials and stored at -70 until required for coating 
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plates. The frozen aliquots should be used within 6 months. 
c) Coating plates with BD MatrigeF^ hESC-qualified matrix 
An aliquot of frozen Matrigel™ was removed from -70 It was thawed on ice until 
liquefied. Then, suitable amount of thawed Matrigel^^ was added to the cold dilution 
medium, DMEM/F12, in 50 ml tube and mixed well. The aliquot volume required 
varies lot-to-lot and must be referred from the Matrigel™ product insert. Immediately, 
the diluted Matrigel™ was used to coat tissue culture-treated plates at room 
temperature for 1 hour before use. For a 6-well plate, 1 ml of diluted Matrigel™ was 
used per well. The plate was swirled to spread the Matrigel™ solution evenly across 
the surface. 
d) HESCs culture in mTeSR™! 
HESCs cultured in mTeSR™! should be seeded on plates coated with matrigel™. To 
seed cells, excess matrigel™ was removed from the culture plate and mTeSR™! was 
added immediately. Cells were seeded at a relatively high density and cells aggregates 
were maintained at approximately 50-60 |im in diameter. The cells were then 
incubated at 37 with 5% CO2 and 95% humidity. The colony morphology was 
different when compared to cells grown on MEF and using normal media formulation. 
For up to 4 days after seeding, colonies appeared transparent and not very densely 
packed with cells. The density and robustness of the colonies increase rapidly after 
this time point and the morphology was changed significantly in the last few days 
before passaging. 
When colonies were large, begun to merge, and had centers that were dense and 
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phase-bright compared to their edges, hESCs were ready to pass. To passage cells, 
spent medium was removed followed by the addition of 1 ml/well of 1 mg/ml dispase. 
To allow dispase to function, cells were incubated at 37 °C for 7 minutes. When 
colony edges appeared folded back, dispase was removed and each well was rinsed 
with 2 ml DMEM/F-12 for 2-3 times in order to dilute any dispase remained. After 
that, 2 ml mTeSR™! was added and cells were scraped off with a cell scraper. The 
detached cell aggregates were transferred to a 15 ml conical tube and each well was 
rinsed with an extra 2 ml mTeSR™! to collect any remaining aggregates. The 2 ml 
cell aggregates was pooled to the same 15 ml conical tube. The 15ml tube was then 
centrifuged at 200 x g for 5 minutes at The supernatant was removed and cells 
were resuspended gently in 2ml mTeSR™! by pipette up and down. While the cells 
were maintained as aggregates, they are plated onto a new plate coated with 
Matrigel™. 
2.4 ESC Characterization (Chemicon Catalogue # SCROOl) 
2.4.1 Alkaline Phosphatase (AP) Staining 
Spent medium of the culture was first aspirated and the culture was washed with PBS. 
Then, ESCs were fixed with 4% paraformaldehyde in PBS for no longer than 2 
minutes. Fixative was then discarded and ESCs were rinsed with IX Rinse Buffer 
containing 20mM Tris-HCl, 0.15M NaCl and 0.05% Tween 20. Suitable amount of 
staining solution, FRY: Naphthol: water in ratio 2:1:1, was added to cover each well 
(i.e. 0.5 ml for a well of a 24-well plate). The culture plate was wrapped by 
aluminium foil and was incubated in dark at room temperature for 15 minutes. After 
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that, the staining solution was disposed and the wells were rinsed with IX Rinse 
Buffer. The cells were than covered with IX PBS to prevent drying and the number of 
colonies expressing AP (red stem cell colonies) can be counted versus the number of 
differentiated colonies (colourless). 
The criteria for AP staining is over 90% of colonies should remain undifferentiated 
and express alkaline phosphatase in the well containing 10^  Units of LIF. 
2.4.2 Immunofluorescence staining 
Spent medium of the culture was first aspirated and the culture was washed with PBS. 
Then, ESCs were fixed with 4% paraformaldehyde in PBS for 15-20 minutes at room 
temperature. After the incubation, ESCs were washed 5-10 minutes twice with IX 
Rinse Buffer. Then, ESCs were permeabilized with 0.1% Triton X-100/ PBS for 10 
minutes at room temperature. Again, ESCs were washed twice for 5-10 minutes with 
IX Rinse Buffer to remove all permeabilization buffer. Next, 4% BSA/ PBS blocking 
solution was applied and incubated for 30 minutes at room temperature. 1:50 SSEA-4 
primary antibody was added to the blocking solution and incubated subsequently for 
1 hour at room temperature. To proceed, ESCs were washed three times with IX 
Rinse Buffer for 5-10 minutes each. Then, secondary antibody in PBS was applied 
and incubated for 30-60 minutes at room temperature. To finish, ESCs were washed 
three times with IX Rinse Buffer for 5-10 minutes each. ESCs in plate wells were 
ready for visualization in IX PBS at this stage. The conditions of antibodies used 
were summarized in Table 4. 
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2.5 Mouse embryonic stem cells (mESCs) culture 
2.5.1 Thawing and plating mESCs 
A vial of mESCs D3 (ATCC) was removed from the liquid nitrogen. It was rolled 
between hands for about 10-15 seconds to remove frost. Then, the vial was immersed 
in a 37 °C water bath and swirled gently with the cap did not submerge. When only an 
ice crystal remains, the vial was taken out from the water bath and sprayed with 70% 
ethanol to reduce microorganisms from the water bath. Cells were transferred into a 
50 ml falcon with 1 ml pipet in a sterile culture hood. Immediately after, 4 ml mESC 
culture media was added drop-wise to cells to dilute the DMSO in the 
cryopreservation media while the falcon was kept shaking to avoid osmotic shock to 
cells. Afterwards, cells were centrifuge at 200 x g, 4 for 5 minutes to remove 
cryoprotectant from cell culture. After supernatant aspirated, the small cell pellet was 
reconstituted in 5 ml mESC culture media. Finally, the cells suspension was added 
into two wells of a 6-well tissue culture plate containing the irradiated CD-I strain 
MEF feeder layer. Plate was incubated at 3 7 � C with 5% CO2 supply. MESC culture 
media was refreshed daily and cells were split every two days in 1:10 ratio. 
2.5.2 Splitting mESCs 
MESCs culture 6-well plate was removed from incubator and spent media was 
aspirated in sterile culture hood. Each well was washed by 1ml PBS to remove any 
serum left behind. Then, 1 ml of 0.05% trypsin/ EDTA was added and the 6-well plate 
was incubated in 37 incubator for 3-5 minutes or until cell dislodged. When 
necessary, the side of the flask was slapped with the heel of my hand to facilitate the 
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detachment of cells. After the plate was transferred to the cell culture hood, 1ml 
medium was then added to each well to stop trypsin reaction. Cell suspension was 
aspirated into 15 ml falcon and centrifuge at 4°C, 200 x g for 5 minutes. Cell pellet 
was then resuspended in mESC undifferentiated medium and one-tenth of cells were 
made up in 2.5 ml per one well of 6-well plate and seeded on fresh CD-I irradiated 
MEF for passage. The plate was returned to the 37 incubator with 5% CO2 supply 
and moved in several quick, short, back-and-forth and side-to-side motions to further 
disperse cells across the surface of the wells. Cell culture media was refreshed daily 
for two to three days before next passage. 
2.5.3 Differentiation of mESCs 
MESCs culture 6-well plate was removed from incubator and spent media was 
aspirated in sterile culture hood. Each well was washed by 1 ml PBS to remove any 
serum left behind. Then, 1 ml of 0.05% trypsin/ EDTA was added and the 6-well plate 
was incubated in 37 incubator for 3-5 minutes or until cell dislodged. When 
necessary, the side of the flask was slapped with the heel of hand to facilitate the 
detachment of cells. After the plate was transferred to the cell culture hood, 1 ml 
medium was then added to each well to stop trypsin reaction. Cell suspension was 
aspirated into 15ml falcon and centrifuge at 4 200 x g for 5 minutes. Cell pellet 
was then resuspended in mESC undifferentiated medium and a portion of cells were 
seeded on MEF for passage. Remaining cells were seeded on 0.1% gelatin coated 100 
mm Petri dish and incubated at 37 °C incubator for 30 minutes. This allowed MEF in 
cells mixture to seed and increased the purity of mESC for differentiation. When the 
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30 minutes incubation was over, cells were pipetted into 15 ml falcon and centrifuge 
at 4 200 X g for 5 minutes. Supernatant was discarded and cell pellet was 
resuspended in 2ml medium to perform cell counting. Differentiation medium was 
added to the required amount of cells to make up to suitable volume, i.e. 800 cells per 
20 |Lil hanging drop. By multi-channel pipette, 50 hanging drops were placed on the 
lid of 100 mm Petri dish carrying 20 ml PBS to prevent drying of hanging drops. Petri 
dish with hanging drops was incubated in a 37 incubator with 5% CO2 supply for 2 
days. 
At differentiation day 2, embryoid bodies (EBs) developed in handing drops were 
checked under inverted microscope to ensure single ball shape EB with normal size 
was formed in every hanging drop. Then, EBs were washed into 100 mm low 
attachment Petri dish in 10ml suspension and incubated in 37 incubator with 5% 
CO2 supply for 5 days. 
At differentiation day 7, each embryoid body was seeded onto one well of 0.1% 
gelatin coated 24-well plate with 1 ml differentiation medium. The EBs were allowed 
to attach in 37 incubator with 5% CO2 supply overnight. The next day was 
differentiation day 7+1 and percentage of beating was begun to count until day 7+21. 
2.5.4 To study the effects of cytokines on mESC differentiation 
After literature review on the types and levels of cytokines expression in mice after 
MI, we decided to study six cytokines, which are IL-la, IL-lp, IL-6, IL-10, IL-18 and 
TNF-a. Three concentrations of each cytokine in 1, 3 and 10 ratio with the reported 
level in-range as shown in Table 5 together with a control were studied. Recombinant 
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cytokine powders were bought from Invitrogen and were added after reconstitution 
into suspension of EBs during day 2 to 5 of differentiation date according to the 
mESC differentiation protocol as 2.5.3 before attachment onto 24-well plates. One 
24-well plate was prepared for each concentration of cytokine or control. Cumulative 
and time-point specific beating curves were obtained and on differentiation day 7+21, 
EBs were collected for mRNA and protein analysis. 
2.6 Lentivirus Packaging 
2.6.1 Transfection of lentiviral vectors into HEK293FT cells 
To package lentivirus with our target expression DNA construct, HEK293FT was 
used as a packaging cell line. Target expression DNA construct was transfected 
together with the packaging plasmids, psPAX2 and pMD2.G into HEK293FT. By 
doing this, lentiviruses were packaged inside the packaging cells and released to the 
culture medium. 
One day before transfection, 6.4X10^ HEK293FT cells were plated on T75 culture 
flask in 10ml growth medium without antibiotics but with additional sodium pyruvate. 
To start transfection, 1.5 ml OPTI-MEM (Invitrogen) was transferred to two 50ml 
falcon respectively. Into one of the 50 ml falcon, 10 |xg psPAX2, 2.5 |ag pMD2.G and 
5 |ig DuetO 11 subcloned with MLC-2v plasmid DNA were added while into another 
falcon holding 1.5 ml OPTI-MEM, 50 |LI1 lipofectamine 2000 was added. The two 
mixtures were allowed to stand at room temperature for 5 minutes. Then the two 
mixtures were pooled together, mixed gently and stood for 20 minutes at room 
temperature. During the 20 minutes incubation time, spent medium of a T75 flask 
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HEK293FT cells was changed to 9 ml OPTI-MEM medium. Then 3 ml of the 
complexes formed in the mixture was added to the HEK293FT cells. The cells were 
then incubated at 37 °C for 6 hours. OPTI-MEM I medium with the complexes was 
changed back to normal medium after 6 hours and lentiviruses were collected at 24, 
36 and 72 hrs post- transfection. 
2.6.2 Lentivirus titering 
On day 1 for lentivirus titration, 3x10^ HEK293FT cells were plated on each well of 
24-well plate in 1ml medium. 6 wells were prepared for serial dilutions of lentivirus 
for each kind of viruses. On the next day, the cells were transduced with five, 5-fold 
serial dilutions in 200 |xl total volume after all cell medium was aspirated. One well 
was left with cell medium as control. Besides using small volume of viruses to 
increase the rate of infection, polybrene was also used to draw viruses, which tends to 
float on top of medium, down to infect cells. 6 |xg/ml working concentration of 
polybrene was used. On day 3，1 ml medium was added to each well to keep cells 
healthy and titering was done on day 4. 
On day 4, spent medium was aspirated from each well and all wells were washed by 
0.5 ml PBS. Then, 0.4 ml 0.05% trypsin/ EDTA was added to each well and the 
24-well plate was put into 37 incubator for 3-5 minutes. When cells detached, 
0.5ml medium was added to stop trypsin reaction. Cell suspension was then 
transferred to separate centrifuge tubes and was centrifuged at 1,000 rpm, 4 for 5 
minutes. After the supematants were discarded, cells were resuspended in 0.5 ml PBS 
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in each tube and cell counting was performed. When all cell counting was finished, 
the cells were subjected to flow cytometry in order to determine the percentage of 
green cells per milliliter of cells, i.e. transduction unit per milliliter. 
2.7 Multiple transduction 
60-70% confluent hESCs on irradiated MEF in 6-well plate was used for virus 
transduction. The spent medium was aspirated and then virus and normal medium 
was added in 1:1 ratio, i.e. 250 |LI1 virus and 250 medium was used in this case to keep 
virus in touch of attached hESC colonies. 6 |ig/ml polybrene was used to draw virus 
down to the bottom of the culture well. After 12 hours, 3 jig polybrene and 1:1 ratio 
of virus and medium in 0.5 ml volume were added additionally as the second trial of 
virus infection. After an extra 12 hours, all viruses in medium was discarded into 90% 
bleach and fresh 1:1 ratio of virus and medium in 0.5 ml medium was added as the 
last trial of virus infection to hESC colonies. 3 \ig polybrene was also added in this 
infection. All of the above steps handled lentiviruses were performed in Biological 
Safety Level II Cabinet and all apparatus including all serological pipettes were 
immersed in 90% bleach for 30 minutes after use and before disposal. 
2.8 Selection of transduced cells by hygromycin 
2.8.1 Determination of hygromycin selection dosage 
Same volumes of suspending hESCs were seeded onto 60 wells of a 96-well plate by 
feeder free system. hESC colonies were cultured continuously by changing mTeSR 
medium daily until 90% confluency reached for selection (around 4-5 days).When 
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90% confluency reached, cells were treated with hygromycin in mTeSR medium at 
concentration of 0, 10, 50, 100, 300 and 500 |ig/ ml for 48 hours. At 48 hours 
post-treatment, MTT proliferation assay was performed to determine the cell viability. 
Each well was washed with 100 [i\ IX PBS twice before adding 100 |LI1 MTT solution 
(3 mg/ml in PBS). The plate was then incubated for 2 hours in 37 °C cell culture 
incubator with 5% CO2 supply. After the 2 hours incubation, 50 |LI1 of 10% SDS 
solution was added to each well to lyse the cells. The plate was mixed gently and put 
into a 70 oven for 15 minutes to dry up SDS. At the end of the incubation, 100 |LI1 
DMSO was added to each well and the plate was let stand at room temperature for 10 
minutes to allow the complete dissolution of the formazan products in DMSO. After 
that, absorbance at 540 nm was measured by a microplate reader (BIO-RAD, model 
3550). Absorbance at 540nm for control well without antibiotic addition was regarded 
as 100% viability and percentage of cell viability of wells with different concentration 
of hygromycin added was calculated by dividing their absorbance by the absorbance 
of control and multiply by 100. A graph of cell viability percentage against 
hygromycin concentration was plotted. The concentration which resulted in 50% cell 
viability was chosen as the selection dosage. 
2.8.2 Selection of stable clones 
HESC colonies transduced with lentiviruses were cultured on feeder free matrigel for 
a week until 70-80% confluency reached before selection. After that, hESC colonies 
with target expression DNA construct were selected by normal feeder-free, mTeSR, 
medium containing 30 |Lig/ml hygromycin antibiotics for 14 days. Colonies remained 
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after 14 days of selection were checked under microscope to confirm the presence of 
green fluorescent signal. 
2.9 Isolation of green fluorescent cells derived from differentiated hESCs 
2.9.1 Collagenase digestion of embryoid bodies into single cells 
Spent medium of the differentiated EBs culture was discarded and the EBs were 
scraped off with a cell scraper. All EBs were transferred into 1.5 ml microcentrifuge 
tube and centrifuge at 200 x g, 4 for 5 minutes. The supernatant was discarded and 
the pellet was washed with 1ml PBS. After all traces of PBS was removed, 1 mg/ml 
sterile collagenase solution with 30 |iM CaCb, 0.12 M NaCl, 5.4 mM KCl, 5 mM 
MgS04, 5 mM Na pyruvate, 20 mM D-glucose, 20 mM taurine and 10 mM HEPES 
was added. The cells were then incubated at 37 °C for up to 30 minutes under 70-80 
rpm rotation. Digested cells were then subjected to centrifugation at 200 x g, 4 °C for 
5 minutes. After that, the digestion solution was discarded and 300 jiil KB solution 
which contained 1 M K2HPO4, 1 M KCl, 1 M MgS04, 1 M EGTA, 1 M Na pyruvate, 
0.1 M creatine, 0.1 M taurine, 2 mM Nai-ATP and 20mM D-glucose at pH 7.2 was 
added. The cells were left at room temperature for one hour under gentle mixing. The 
tube was rotated by hand every 10 minutes. Cell suspension was then passed through 
a sieved capped into a flow tube for Fluorescence Activated Cell Sorting (FACS) 
subsequently. The cells were kept on ice before and after sorting. 
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2.9.2 FACS 
In order to recognized the green cells derived from the differentiated hESC 
population, control cells without green signal and positive control cells transduced 
with vector containing a constitutive promoter, UBC, driving GFP were first run to 
gate the area where green cells should appear. Negative control cells, non-green and 
green populations from the positive control were collected. Then, our target cells 
transduced with lentiviral vector harboring cardiac-specific promoter hMLC-2V 
driving the expression of GFP were run. Both green and non-green populations were 
sorted for subsequent analysis. 
2.10 Gene expression study 
2.10.1 Primer design 
Primers for real-time PCR were designed using Primer Express 3.0 (Applied 
Biosystems) that also allows for an easy design of compatible TaqMan probes, for use 
in real-time PCR or end-point PCR analysis. Basically, the primers were designed to 
flank 150-300 base pairs of the target gene sequence with an annealing temperature of 
58-60 The sequences of the qPCR primers used in this study were listed in Tables 
6 and 7. 
2.10.2 RNA extraction 
Trypsinized cells collected in 1.5 ml microcentrifuge tube were first washed with 1 
ml PBS twice. Next, 1 ml TRIzol reagent (Invitrogen) was added to the pellet and 
pipetted up and down for several times to lyse the cells. The cells in TRIzol were 
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allowed to stand at room temperature for 5 minutes. After that, 200 |xl chloroform was 
added and mixed by vortex for 15 seconds. The tube was allowed to stand at room 
temperature for 3 minutes. Subsequently, the mixture was centrifuged at 12,000 x g, 
4°C for 15 minutes. The upper aqueous phase containing mRNA was transferred to a 
new eppendorf and mixed with 500 |xl isopropanol. RNA was allowed to precipitate at 
-20 °C overnight. 
On the next day, the sample was centrifuged at no more than 12,000 x g, 4 for 10 
minutes. The pellet was washed with 75% ethanol and centrifuged at 7500x g, 4 
for 5 minutes. After the supernatant was discarded, the pellet was air-dried for about 5 
minutes. RNA pellet was then dissolved in 15 |LI1 DEPC-treated water. 
2.10.3 DNase treatment 
7.5 III raw RNA was added in 1.5 |il DNase buffer, 4 |LI1 DNase and DEPC-treated 
water to make up a final reaction volume of 15 |iL The reaction mixture was 
incubated at 3 7 � C for 30 minutes in a thermal cycler, PTC-200 DNA Engine, (Petlier 
Thermal Controller). After the incubation, 1 |LI1 stop solution was added and the 
reaction mixture was incubated at 65 for 10 minutes to inactivate the DNase. 
DNase-treated RNA was quantified by spectrophotometric analysis. 
2.10.4 Synthesis of double-stranded cDNA from total RNA 
2 |xg DNase treated RNA was mixed with 5 |iM oligo dT, ImM dNTP mix and 
DEPC-treated water to make up a total volume of 10 |LI1. This was incubated at 65 
for minutes and then placed on ice for at least 1 minute. Then, cDNA master mix 
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which contained 2X RT buffer, 10 mM MgCb, 20 mM DTT, 40 units RNaseOUT and 
200units Superscriptlll was added to the RNA/ primer mixture in 1:1 ratio. The 
mixture was incubated at 50 °C for 50 minutes followed by terminating the reaction at 
85 for 5 minutes. The cDNA was then kept on ice and 1 |LI1 RNase H was added 
followed by an incubation at 37 for 20 minutes. cDNA was stored at -20 until 
use. 
2.10.5 Quantitative real-time PGR 
Quantitative real-time PGR with Power SYBR Green PGR Master Mix (Applied 
Biosystem) was used to measure the mRNA expression of specific target genes in 
cells. SYBR Green was a dye that can bind to the minor groove of double stranded 
DNA which exhibited little fluorescence in solution but strong fluorescence when 
bound to DNA. When SYBR Green bound to the DNA, the intensity of fluorescent 
signal increased proportionally. This gave an amplification plot from which threshold 
cycles can be determined for subsequent calculation of gene expression level between 
different samples. 
Real-time PGR was performed in triplicate in a 20 fil reaction mixture of 1 )LI1 C D N A 
sample, 3 |LIM primer mix, 1 |il Power SYBR Green Master Mix (Applied Biosystem) 
and sterile nano pure water. A separate mixture for beta-actin was included as an 
internal control for each trial for the target genes. The mixture were loaded onto a 
96-well PCR plate (ABI Prism, Applied Biosystem) and sealed. The PGR was 
performed on an ABI Fast 7500 real-time PCR machine with standard profile of 1 
cycle of 50°C for 2 minutes, 9 5 � C for 10 minutes, 40 cycles of 9 5 � C for 15 seconds, 
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60 for 1 minute. Quantification of gene expression was carried out using Fast SDS 
program with auto-Ct settings. The threshold cycle number (Ct) value defines the 
number of cycles for which SYBR Green signal generated was high enough to be 
recognized by the machine and the Ct values should fall in the log phase of PCR 
amplification. After normalization with the endogenous control, the AACt value was 
calculated with reference to the control sample. 
2.10.6 Quantification of mRNA expression 
After the cycles of real-time PCR have been completed, threshold for different gene 
expression were checked and the threshold should fall in the log phase of PCR 
amplification. Threshold cycle (Ct) for housekeeping gene expression was subtracted 
from Ct of target gene to obtain ACt. Then ACt of control sample was subtracted 
from A C t of experimental sample to obtain A A C t . Fold change was then 
calculated as While A A C t of control sample should be equal to 0, fold 
change of control should be equal to 1. 
2.11 Protein expression study 
2.11.1 Crude protein extraction 
Cells collected in 1.5 ml microcentrifuge tube were washed with ice-cold IX PBS 
twice before treating with 4 volumes of modified Radioimmunoprecipitation Assay 
(RIPA) lysis buffer with protease and phosphatase Inhibitors (Roche). After the 
addition of protease and phosphatase inhibtitors included RIPA buffer, the cells were 
pipetted up and down to mix and then left on ice for 5 minutes. The cell lysate was 
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subjected to 20 minutes centrifugation at 20,000 g, 4 The clear supernatant was 
then collected for protein concentration measurement. 
2.11.2 Quantitation of protein samples 
Protein concentration of extracted cell lysate was analyzed with Bradford Assay. 
Protein concentration of cell lysate and standard proteins samples were measured, in 
which, 3 |il of sample was mixed with 200 |LI1 of Bradford reagent on a flat bottom 
96-well plate. After 5 minutes incubation at room temperature, the absorbance was 
measured by a microplate reader (Model 3550, BIO-RAD) at wavelength 595 nm. A 
standard bovine serum albumin (BSA) curve was obtained by using 0.1, 0.2, 0.4, 0.8， 
1.2，1.6 and 2 mg/ ml BSA to determine the protein concentration of samples. 
2.11.3 SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed to separate the cellular proteins according to their electrophoretic mobility 
which was determined by the molecular weight of proteins. SDS-polyacrylamide gel 
was set to 5-12.5% depending on the protein target of interest. Cell lysate with equal 
amount of crude proteins were mixed with IX SDS gel loading buffer and subjected 
to boiling for 5 minutes before loading into the gel. Pre-stained Novex Sharp 
Standard marker (10 ^l) was loaded in parallel as a standard molecular weight marker. 
The gel was run at 120-150 volts for 1-1.5 hours. 
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2.11.4 Western Blot 
After electrophoresis, the stacking gel was discarded and the running gel was 
equilibrated in transfer buffer for about 3 minutes. During the equilibration, a piece of 
Immobilon™-P Transfer Membrane was fixed with 100% methanol for 15 seconds 
and then equilibrated in transfer buffer. Two sets of 3MM Whatman chromatography 
papers (Kents, UK) were soaked in transfer buffer. Transfer was performed with the 
running gel and the transfer PVDF membrane placed in between two sets of 3 pieces 
of chromatography papers. Air bubbles were excluded using a roller. The electroblot 
transfer was performed at 100 volts for 1-3 hours with a Trans-blot SD wet transfer 
tetra-cell (Bio-Rad). 
After transfer, the membrane was incubated in 5% blotting milk in IX PBST buffer 
with constant and gentle shaking for an hour to block the non-specific binding sites 
of antibody. Appropriate amount of primary antibody was added directly to the 
blotting solution and incubated with constant shaking at 4 °C overnight. After 
primary antibody binding, the membrane was briefly rinsed with IX PBST washing 
buffer and then washed for three times with 10 minutes each with constant shaking. 
Suitable amount of secondary antibody was added to 5% milk in IX PBST and 
incubated no more than 1 hour at room temperature with gentle shaking. Detailed 
information for the antibodies used in this study and the dilution of primary and 
secondary antibodies used were listed in Tables 8 and 9. After the antibody binding, 
the membrane was washed for three times with 10 minutes each with constant 
shaking. 
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2.11.5 Western blot luminal detection 
Luminal detection solution was prepared by mixing equal amount Western 
Lightening™ Chemiluminescence Reagent Plus Enhancing reagent and oxidizing 
reagent (Perkin Elmer). The membrane was briefly rinsed in IX PBST washing buffer 
and then dried by touching the edge of the membrane against a paper towel. The 
membrane was then immersed in an inverted position in the luminal detection 
solution and allowed to stand for 1 minute. The membrane was then covered by a 
transparent film and placed in a film cassette. A sheet of X-ray film (Fujifilm) was 
placed on top of the membrane in a dark room and allowed to expose for 10 seconds 
to 5 minutes. The film was developed with a Kodak film developer. 
2.11.6 Quantification of protein expression 
Image obtained from luminal detection was loaded in AlphaEase FC software of 
Alpha Innotech. By SpotDenso function under Analysis Tools option, same object 
area was assigned and fitted for each band for quantity comparison. Auto background 
and signal inverting icons were clicked to generate fair individual signal quantified as 
digits from black images. Quantified digits were output into excel file and sample 
signals were divided by the control signal. Hence, the protein expression level for 
control was always equal to 1 and the quotients obtained were the fold change for 
samples. 
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Primers used in this project 
Table 1: Primers for MLC-2v amplification 
Name Sense Sequence Length(bp) Tm(�C) 
MLC2v_Duet_F F |5' ACT GXCTTA ATT A A CGAGCTCTAAGCTTCACATATGC 3' 37 64 
MLC2v_Duet_R R' [s' ACTGACGG7MCCTGAATTCTACGCGTCGACAG 3' | 32 | 69 
Key: ACTGAC: protection cap 
TTA ATT A A : Pad restriction site 
GGTACC: Kpnl restriction site 
F': Forward 
R': Reverse 
Table 2: Primer for colony check for successful ligation 
Name Sense Sequence Length(bp) TmfC) 
MLC2v_check_F F 15' CCC GAA GGA ATA GAA GAA GA 3' I 20 58 
MLC2v_check_R R' 15’ AGC CCA GG A AC A ATA A AT ACT 3' | 21 | 47 
Key: F': Forward 
R': Reverse 
Table 3: Primers for DuetOll-MLC2v sequencing 
Name Sense Sequence Length(bp) Tm(°C) 
MLC2v_seq_l F' |5'(k^GAAAGAATAGTAGACATAAT 3' I 22 | 54.8 
MLC2v_seq_2 F' 5' CGAGCTCTAAGCTTCACATATGC 3' ~ 3 66.4 
MLC2v_seq__3 F' 5' TCCGCCTCCTGGGTTCAA 3' 67.9 
MLC2v_seq_4 F 一 5' ACGCCTAGCTCCATCACT 3' 18~" 58.4 
MLC2v_seq_5 F ‘ 5' CCACCACGCACAGCTATT 3' 18 60.6 
MLC2v_seq_6 5' AGTATTTATTGTTCCTGGGCT 3' " ^ T " 60.2 
MLC2v_seq_7 F [s' AACTACAAGACCCGCGCC 3' 18 64.7 
Key: F': Forward 
R': Reverse 
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Table 6: Primers of cardiac markers for cytokine effects on mESC differentiation 
Gene name Sense Sequence amplicon size (bp) 
a-Actinin F 15' ACT ACC ACG CAG CGA ACC 3' 277 
R' 5' TCC CCT GAA ATG ACC TCC 3' 
Factor F 5' TCG TCT TGG CCT TTT GGC T 3' “ 106 
(ANF) R' 5' TCC AGG TGG TCT AGC AGG TTC T 3' 
g-Myosin Heavy Chain F ~ 5' AGC TGA CAG GGG CCA TCA T 3' 180 
(a-MHC) R' 5, AC A TAC TCG TTC CCC ACC TTC 3' 
Cardiac Actin F 5' CCA GCC CAG CTG AAT CC 3' 106 
R' 5' CCA TTG TCA CAC ACC AAA GC 3' 
Cardiac Troponin I 5' AGG GCC CAC CTC AAG CA 3’ 103 
(c-Tnl) R' 5' GGC CTT CCA TGC CAC TCA 3’ 
Cardiac Troponin T 5' TTC ATG CCC AAC TTG GTG CC 3' 260 
(c-TnT) R' 5' CTC TCT TCA GCC AGG CGG TTC 3' 
Myosin Light Chain, 5' GGG TAA GTG TTC CGG AGG AA 3' 98 
Atrial (MLC-2A) R' 5' GAG CTT CTC CCC GAA GAG T 3' 
P-Actin F 5' AGA GGG AAA TCG TGC GTG AC 3' 138 
R' 15' CAA TAG TGA TGA CCT GGC CGT 3' | 
Key: F: Forward 
R': Reverse 
Table 7: Primers of cardiac markers for qPCR of FAC sorted hESCs 
Gene name Sense Sequence amplicon size (bp) 
AASDH F 15' GCG TTT CCA TCA TTG ACA GTT C 3' 100 
R' 5' TGG TCG CCC AAC TTG ATA CC 3' 
c-Tnl F 5' CCC TGC ACC AGC CCC AAT CAG A 3' 250 
R' 5' CGA AGC CCA GCC CGG TCA ACT 3丨 
C-TnT F 5' GGC AGC GGA AGA GGA TGC TGA A3, 150 
R' 5' GAG GCA CCA AGT TGG GCA TGA ACG A 3' 
hARP F 5' CAC CAT TGA AAT CCT GAG TGA TGT 3' 113 
R' 5' TGA CCA GCC CAA AGG AGA AG 3' 
M L C - 2 V F 5 ' G G C G C G T G A A C G T G A A A A A T 3 ' 2 0 0 
R' 5' CAG CAT TTC CCG AAC GTA AT 3' 
Nkx2.5 F' 5' GGT CTA TGA ACT GGA GCG GC 3' 322 
R' 15' ATA GGC GGG GTA GGC GTT AT 3' 
Key: F': Forward 
R': Reverse 
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Antibodies used in this project 
Table 4 : Antibodies used for ESC characterization 
Name Category Company Catalogue No. Dilution 
Anti SSEA-1 monoclonal Chemicon MAB43Q1 1:50 
Anti SSEA-4 monoclonal Chemicon MAB4304 1:50 
Fluorescein goat anti-mouse IgG (H+L) Polyclonal Molecular Probes F2761 1:100 
Table 8: Primary antibodies used for western blot for cytokine effect on mESC differentiation 
Name Category Company Catalogue No. Dilution 
Anti-g-actinin monoclonal Sigma A7811 1: 1000 
Anti- cardiac Troponin T monoclonal abeam ab8295 1:1000 
Anti- heavy chain cardiac myosin monoclonal abeam ab50967 1: 500 
Anti-cardiac actin monoclonal ARP 03-61075 1: 1000 
Anti-GAPDH monoclonal Ambion AM430Q 1: 5000 
Anti-beta-tubulin monoclonal Santa cruz sc-5274 1:200 
Table 9: Secondary antibodies used for western blot for cytokine effect on mESC differentiation 
Name Category Company Catalogue No. Dilution 
Rabbit Anti-Mouse Immunoglobulins/ HRP polyclonal Dako P0260 1:5000 
Goat Anti-Rabbit Immunoglobulins/ HRP polyclonal Dako P0448 1:5000 
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Cytokines used in the study of cytokines, effect on mESC differentiation 
Table 5: Concentration of cytokines used to study the effect on mESC differentiation 
Cytokine Concentration (ng/ ml) Solvent 
IL-la 1,3, 10 I 0.5mg /ml BSA 
IL-lp 0.3, 0.9, 3 ice-cold sterile distilled water 
IL-6 0.5, 1.5, 5 IQQmM acetic acid 
IL-IQ 1 ,3 ,10 Q.5mg /ml BSA 
IL-18 0.3, 0.9, 3 ice-cold sterile distilled water 
TNF-g 0.03,0.09,0.3 Q.5mg /ml BSA 
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Chapter 3 
Purification of cardiomyocytes derived from the 
differentiated hESCs 
3.1 Subcloning 
In this section, targeted lentiviral vector with MLC-2v, a cardiac specific promoter for 
GFP expression cassette was prepared. With the DuetOll lentiviral vector ^^(Fig. 3.1), 
the original constitutive UBC promoter upstream to the GFP gene was excised by 
restriction digestion with Pad and Kpnl restriction enzymes. The digestion products 
were shown in Fig. 3.2. 
On the other hand, the cardiac specific promoter, MLC-2v, was amplified from 
pKM2L-phMLC2v as shown schematically in Fig. 3.3 with the addition of Pad and 
Kpnl restriction sites by the designed primers as shown in Table 1. PGR products 
were analyzed on an agarose gel and single band of MLC-2v promoter was shown in 
Fig. 3.4. After restriction digestion of the amplified DNA fragment with Pad and 
Kpnl, sticky ends which allowed ligation of MLC-2v promoter to the linearized 
DuetOll lentiviral vector were generated. Ligation was performed at 16�C overnight 
and the vector map of the resultant vector was shown in Fig. 3.5. On the next day, the 
ligation products were transformed into DH5a strain of E.coli. Positive clones were 
checked by colony PCR on the following day. Clones with the target band as seen on 
Fig. 3.6 were re-grown in LB and a small scale preparation of plasmids was 
performed. Restriction digestions with Apal and MM were carried out to reconfirm 
the insertion of MLC-2v promoter. Result of Apal and MM restriction digestion was 
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shown in Fig. 3.7. 
3.1.1 Linearization of DuetOll and excision of UBC promoter 
Pad Kpnl 
CMV| I f P G ^ I ^ ^ ^ A U 3 I R|U5 
Fig. 3.1 Schematic diagram of lentiviral vector, DuetOll 
1 / Extracted for ^ 
Fig. 3.2: Gel photo showing the bands after Pad and Kpnl restriction digestion of 
DuetOll lentiviral vector. The large fragment with 9566bp without UBC promoter 
was extracted and purified for subsequent cloning with a cardiac specific promoter, 
M L C - 2 V . 
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3.1.2 PCR cloning of MLC-2V 
S o ^ ； 。 5 
§ 05 S o </) 5 
论丄 M L C - 2 V z f 7- ^ 
X \ • I 1 1 / 
C ^ ^ ^ repor ter g e n e po lyA \ 
p K M 2 L - p h M L C 2 v } 
or l K a n � 
Fig. 3.3: Schematic diagram showing the amplification of MLC-2v from plasmid 
pKM2L-phMLC2v with forward and reverse primers flanking the MLC-2v promoter 
listed in Table 1. 
1kb DNA 
ladder 
^ M L C - 2 v 
2 3 5 7 b p 
Fig. 3.4: Gel photo showing the specific bands after amplification of MLC-2v 
promoter by PCR. 
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3.1.3 Ligation of MLC-2v promoter to linearized DuetOll 
r . Mlul 
NotI 
J ^ X ^ ECONI 
/ AmpR \ 
Bst1107 / \ 
s 認:f 
Duet011-MLC-2v • BsaBI 
k h M L C 2 v j 
/ 
GFP / / 
— • r I Mlul 
RsrII ！ Kpnl 
Sgfl I Asp718 
PshAI BsrGI 
Xhol 
Fig. 3.5: Vector map of the resultant lentiviral vector with MLC-2v subcloned into the 
DuetOll vector and replaced the UBC promoter to drive the GFP gene expression, 
namely DuetO 11 -MLC-2v. 
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3.1.3.1 Colony PCR to screen for positive clones 
Fig. 3.6: Gel photo showing the colony PCR amplification of MLC-2v promoter 
among 1 to 46 randomly picked colonies after ligation and transformation. 13 out of 
46 colonies had successful MLC-2v insertion with single band detected. 
3.1.3.2 Restriction digestion to confirm the success of ligation 
^ ^ U n c u ^ A p a ^ ^ l 
4 k b 今 
• Expected size: 
Apal: 3657bp, 8266bp 
Mlul: 4771 bp, 7152bp 
Fig. 3.7: Gel photo shows the products of restriction digestion of resultant lentiviral 
vector using Apal and Mlul enzymes to check for the presence of MLC-2v promoter. 
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3.2 Lentivirus (LV) packaging 
To package LV with the targeted expression vector, the target DuetOl l-MLC-2v 
vector along with two packaging plasmids, psPAX2 and pMG2.G were transfected 
into the packaging cells, HEK293FT by lipofectamine 2000. Transfection efficiency 
was checked under fluorescent microscope (Fig. 3.8). At 24, 36 and 48 hrs 
post-transfection, supernatant, which contained the interested LVs was collected, 
filtered and frozen in small aliquots. After the LV titering was performed by flow 
cytometry as shown in Fig. 3.9 and a standard curve for LV titering of Fig. 3.10 was 
constructed, the LVs packaged were ready for use with titer of 3.5 X 10^ TU/ml. 
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3.2.1 Transfection 
DuetOll DuetO 11 -MLC2v 
9BBBHRHBHS SBHBMHSHSni 
Fig. 3.8: HEK293FT under fluorescence microscope to check for the transfection 
efficiency of the target lentiviral vector together with two packaging plasmids. While 
UBC is a constitutive promoter, green fluorescent signal was observed after the 
transfection of DuetOll. For MLC-2v, which is a cardiac specific promoter, GFP was 
not expressed after the transfection with DuetO 11-MLC2v. 
Key: DuetOll = UBC-GFP-PGK-hygR 
DuetO 11-MLC2V 二 MLC2v-GFP-PGK-hygR 
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3.2.2 LV titering 
Con t ro l 一 no v i r us LV-Due t011 
UBC(52)-1 
� l i | W U n , , , | ,1 丄 , 成 知 . , 1 
1(1� id' 1(= 10^  10� 10* 10^  FITC-A FITC-A 
LV-Duet011 (5X d i lu ted) LV-Duet011 (25X di lu ted) 
UBC(52V2 UBC(52V3 
•_:•‘,1.1 I J 10^  10^  10 ‘ 10^  10^  10^  10* 10® FITC-A I FITC-A 
LV-Duet011 ( 1 2 5 X d i lu ted) LV-Duet011 ( 6 2 5 X d i lu ted) 
O^  UBC(52)4 UBC(52>5 
° I I I I丨丨，1 1111111； …"I—I 11 I I i i i i i 1 , 1 , 1 1 1 1 rVTrrVnT.-r I 丨- 丨 I —rJ 
10' 10' 10® 10' 10' 10® FITC-A FITC-A 
Fig. 3.9: The comparison of FITC signal between normal HEK293FT cells and 
HEK293FT cells transduced with different dilutions of LV packaged with DuetO 11 
with UBC-GFP by flow cytometry. An obvious shift of the peak from FITC negative 
to FITC positive region was noted between control HEK293FT cells and those 
transduced with undiluted LVs. As the LVs became more and more diluted, the peak 
shifted from the FITC positive region back to the FITC negative region gradually. 
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Transduction Units (TU) 
=(No. of cells) X (percentage of FITC positive cells) x (dilution factor) x 5 / 100 
For LV-DuetOll, 
Transduction units of serial diluted viruses were calculated with the above formula 
and standard curve plotted as follow: 
No dilution: (7.2 X 10^) (97.375) (1) X 5 / 100 = 3.505 x 10^ TU/ ml 
5X dilutions: (5.1 X 10^) (49.58) (5) X 5 / 100 = 6.325 X 10^ TU/ ml 
25X dilutions: (5.95 X 10^) (11.875) (25) X 5 / 100 = 8.84 X 10^ TU/ ml 
125X dilutions: (7.35 XIO^) (2.675) (125) X 5 / 100= 1.23 X lO? TU/ ml 
625X dilutions: (1.81 X 10^) (2.475) (625) X 5 / 100= 1.4 X 10^ TU/ ml (outlier) 
Standard curve for lentivirus titering 
14 : ——I 
” y=°2,89x +0.5175 , 
l i i i i i i i i i i i i i i i l i i l i r ” ^ ^ “ 
S R = 0.9957 ^ ^ 
I 10 
r 8 ~ y Z — ~ 
\ 6 y Z 
I 2 ^ ^ — 
U H Q ： I [ L . L _ _J 
0 1 2 3 4 5 
Serial dilutions 
Fig. 3.10: Standard curve for LV titering 
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3.3 hESC culture 
Fig. 3.11: The appearance of a healthy undifferentiated hESC colony with sharp 
colony edge and homogenous cells growing on MEF feeder layer. 
Fig. 3.12: A close look of a hESC colony growing on MEF feeder layer. 
6 6 
Chapter 4 — Results (Part II) 
3.4 Multi-transduction of hESCs with LVs 
Using the healthy hESCs grew on MEF feeder layer as shown in Fig. 3.11 and Fig. 
3.12, multi-transduction was performed by direct addition of LVs which contained the 
target expression vector onto hESC culture. LVs were added in 1:1 ratio with normal 
hESC culture medium. 0.6|xg/ml polybrene was added to increase the LV transduction 
efficiency by drawing LVs down to the bottom of culture wells and allowing LVs to 
infect hESCs. 
After 12 hrs, the second transduction was performed by simply adding 1 volume of 
LVs diluted with hESC culture medium in 1:1 ratio with polybrene into hESC culture. 
Then, after another 12 hrs, the third transduction was performed. This time, fresh LVs 
were applied and LVs added in the first and second attempt were discarded. On the 
next day, all residual LVs were aspirated and normal hESC culture medium was 
provided to allow recovery of hESCs after transduction. HESC colonies transduced 
with LV-DuetOll fluoresced green under the microscope as shown in Fig.3.13. 
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B — i 
w 
i m m m 
• 
Fig. 3.13: HESC colonies examined under fluorescent microscope to check for the 
success of multi-transduction by LVs. A. hESCs transduced with LV-DuetO 11-MLC2v; 
B. hESCs transduced with LV-DuetOll ； C. Control hESCs not transduced with LVs. 
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3.5 Differentiation after transduction 
After the multi-transduction, differentiation was performed to check if LV 
transduction had a negative impact on cardiac differentiation of hESCs. In the culture, 
beating EBs were observed in both targeted hESC line transduced with 
LV-Duet011-MLC2v and the positive control hESC line transduced with LV-DuetOll. 
Interestingly, green cells were observed in differentiated hESCs transduced with 
LV-DuetO 11 -MLC2v as shown in Fig. 3.14. This was the first time green cells were 
seen in this hESC line and they were speculated to be cardiomyocytes which have the 
necessary transcription factors to bind the transduced MLC-2v promoter and allow 
the expression of GFP gene downstream. 
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L V - D u e t 0 1 1 - M L C - 2 V L V - D u e t 0 1 1 
mm 
Fig. 3.14: Phase contrast (upper row) versus fluorescence (lower row) images of 
differentiated hESCs which were transduced with LV-DuetO 11 -MLC2v (left column) 
or LV-DuetOll (right column) respectively before hygromycin selection. Red arrows 
indicate the beating clusters. Some green cells were noted in hESCs transduced with 
LV-DuetO 11 -MLC2v while much more robust expression of GFP was present in 
hESCs transduced with LV-DuetOll. 
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3.6 Antibiotic selection 
In order to screen for positive clones which were transduced with LVs, hygromycin 
selection was performed since hygromycin resistant gene was also included in the 
expression vector. 
The feeder free system for the hESC culture was employed in order to determine the 
antibiotic dosage before the selection process. Characterization of hESCs was carried 
out to ensure the undifferentiated status of the hESCs in that system as there were 
obvious changes of cell morphology. AP staining and immunofluorescence staining of 
pluripotent marker showed that hESCs were well-kept in undifferentiated state (Fig. 
3.15 and Fig. 3.16). Subsequently, hygromycin dosage for selection was determined 
by MTT assay with the feeder free system. A graph of percentage of cell viability 
against concentration of hygromycin was plotted as Fig. 3.17 and IC50 was shown to 
be 21.27 土 3.01|ig/ml, therefore 30 |Lig/ml was chosen as the working concentration 
for hygromycin selection. 
After hygromycin selection at 30fig/ml for 14 days, hESCs transduced with 
LV-DuetOl 1 -MLC-2v remained and appeared healthy. For hESCs transduced with 
LV-DuetO 11, colonies remained and still showed fluorescence. Representative images 
were shown in Fig. 3.18. In contrast, control hESCs were all killed after 14 days of 
selection, (data not shown) 
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3.6.1 Characterization of hESCs on feeder free system 
3.6.1.1 Alkaline Phosphatase (AP) staining 
A 
# 瑪 
Fig. 3.15: A and B show two different hESC colonies that were grown on a feeder 
free system stained in purplish red. This indicated that AP was highly expressed in 
both of them. In fact, all hESCs subjected to AP staining showed expression of 
similar levels of AP. 
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3.6.1.2 ImmunoStaining with pluripotency marker 
SSEA-4 SSEA-1 
I . 
I r 丨 _ _ ？ , 一 攀 r ； ：：.•: 
卜 , 寺 一 、'/ / 
Fig. 3.16: HESC colonies that were grown on feeder free system were stained with 
anti-SSEA4 and anti-SSEAl antibodies and were examined under fluorescent 
microscope. HESC colonies were stained positively with SSEA-4 but not SSEA-1, 
indicating that they were in an undifferentiated state. 
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3.6.2 Determination of hygromycin dosage by MTT assay 
% cell viability at different concentration of hygromycin 
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Fig. 3.17: A graph showing the result of MTT assay. An IC50 was 21.27 ± 3.01 )j,g/ml. 
30 )Lig/ml was therefore chosen as the dose for positive clone selection process. 
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3.6.3 hESCs after selection in feeder free system 
LV-Duet011-MLC-2V L V - D u e t 0 1 1 
• • 
Fig. 3.18: Phase contrast (upper row) and fluorescence images (lower row) of hESCs 
transduced with LV-Duet011-MLC2v (left column) and LV-DuetOll (right column) 
after 14 days of hygromycin selection at 30|ig/ml. 
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3.7 Differentiation of hESCs after selection 
Before FACS for identification and purification of green cells derived from 
differentiated culture of hESCs transduced with the targeted expression vector, 
differentiation of the hESCs line transduced with LV-DuetO 11 -MLC2v, positive 
control hESC line transduced with LV-DuetOll and control hESC without 
transduction were performed. Average percents of beating EBs of the control line and 
transduced lines from differentiation day 1 to 25 were plotted as Fig. 3.19. 
—*— Duet011-MLC-2v, n = 3 
DuetOl 1, n = 3 
40-1 ^^CTL, n = 3 
35 — 丁 丁 丁 丁 丁 •_ 
^ 30- T T � /•••••••••••• 
^ - . I f - , / 
二 25- I � 
m - u L , " : 二 " , ( ) ' ( ) ( ) 
^ 1 5 ： ------土士i 
力,，r)〇inini丄丄丄 
？ s； i f P 丄 1 
^ 0- 晷 
_5 "I 1 1 1 ‘ 1 ‘ 1 ‘ 1 ‘ 1 ‘ 
0 5 10 15 20 25 
Day of differentiation (7+x) 
Fig 3.19: Beating curves for control, differentiated hESCs transduced with 
LV-DuetOll and LV-DuetO 11 -MLC-2v. The average percentage of beating EBs were 
30.7%, 25.3% and 22.9% for hESCs transduced with LV-DuetO 11-MLC2v, 
LV-DuetOll and control respectively, indicating that the differentiation potential of 
hESCs was not negatively affected by transduction. 
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3.8 FACS 
A representative set of FACS data was taken and shown below is the gating criteria 
for the classification of cells. PI was all the events examined by the FACS machine 
with cell debris eliminated. P2 and P3 were events within PI. P2 was classified as 
non-green cells with most control cells appearing here. P3 was classified green cells 
with hESCs transduced with LVs expressing UBC-GFP appearing in this area. 
Therefore, the cells that appeared in P3 transduced with LVs expressing 
MLC-2v-GFP were considered the targeted cells derived from differentiated hESCs 
that were subjected to further investigations. 
However, not all cells in P3 were green in the case of differentiated hESCs transduced 
with LV-DuetO 11 -MLC2v. This is because there were also some events (5.1%) in P3 
in the control sample as shown in Fig. 3.20. Note that it was technically impossible to 
gate P3 in control sample with 0% event since these differentiated samples had mixed 
populations of cells. The percentage of green cells sorted from the positive control 
hESCs transduced with LV-DuetO 11 and the target hESC transduced with 
LV-Duet011-MLC2v were 63.3% and 7.2% out of the parent cell population 
respectively as shown in Fig. 3.21 and Fig. 3.22. The data of FACS (n=3) was 
summarized in Table 10. 
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Fig. 3.20: The SSC vs FSC plot, SSC vs FITC plot of control differentiated hESCs 
and the population hierarchy showing the respective percentages of cells in different 
gates. The percentage of green cells in P3 was 5.1% of parent cell population. 
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Tube： U B C 
P o p u l a t i o n # E v e n t s % P a r e n t % T o t a l 
• A l l E v e n t s 6 3 , 1 1 0 1 0 0 . 0 
H I P 1 3 0 , 0 0 0 4 7 . 5 4 7 . 5 
I — H P 2 6 , 7 8 4 2 2 . 6 1 0 . 7 
L - B P 3 1 9 , 0 0 5 6 3 . 3 3 0 . 1 
Fig. 3.21: The SSC vs FSC plot, SSC vs FITC plot of differentiated hESCs 
transduced with LVs expressing UBC-GFP and the population hierarchy of showing 
the respective percentages of cells in different gates. The percentage of green cells in 
P3 was 63.3% of parent cell population. 
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P o p u l a t i o n # E v e n t s % P a r e n t % T o t a l 
• A l l E v e n t s 5 2 , 3 7 0 1 0 0 . 0 
H B P 1 3 0 , 0 0 0 5 7 . 3 5 7 . 3 
[ - B P 2 2 3 , 6 2 7 7 8 . 8 4 5 . 1 
2 , 1 5 4 7 . 2 4 .1 
Fig. 3.22: The SSC vs FSC plot, SSC vs FITC plot of differentiated hESCs 
transduced with LVs expressing MLC-2v-GFP and the population hierarchy showing 
the respective percentages of cells in different gates. The percentage of green cells in 
P3 was 7.2% of parent cell population. 
Control LV-DuetO 11 LV-DuetO 11 - M L C ~ 
PI: All events with cell debris e x c l u d e d 5 5 . 6 ± 4 . 5 6 4 8 . 7 ± 0.86 55.8 ± 0.93 
P2: FITC negative population of PI 86.5 土 4.00 25.2 土 6.68 83.1 土 4.57 
P3: FITC positive population of PI 3.6 ± 1.03 57.4 ± 9.62 5.0 土 1.24 
Table 10: Summarized data for the percents of events in different gates of the 
differentiated control hESCs, differentiated hESCs transduced with LV-DuetOll and 
LV-DuetO 11 -MLC-2v. Data are expressed as mean 士 SEM from three separate 
experiements. 
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3.9 QPCR of cells after FACS 
In order to test whether the sorted green population was enriched with 
cardiomyocytes, RNA extraction of different groups of sorted cells was performed. 
After reverse transcription of RNA into cDNA and confirmation of cDNA quality by 
PCR, qPCR was performed to check for the cardiac specific gene expression level. 
The cardiac specific genes examined were Nkx2.5, c-Tnl, c-TnT and MLC-2v. 
Unfortunately, the green population sorted from differentiated hESCs transduced with 
MLC-2v-GFP did not show significant increase in expression of cardiac specific 
genes as shown in Fig. 3.23 to Fig. 3.26. In contrast, an increased expression of 
C-TnT in a non-green population sorted from the targeted line transduced with 
LV-DuetO 11 -MLC2v was observed (Fig. 3.25). In addition, a significant decrease of 
MLC-2v expression was observed in both green and non-green populations of hESC 
line transduced with LV-DuetO 11 as shown (Fig. 3.26). 
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3.9.1 Gene expression of Nkx2.5 
35-
30-
� 25- T 
D) 
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05 
6 15- I 
？ 10- T 
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5- I 
0 - ： 
LJ , 1 1 1 1 
CTL MG MXG UG UXG 
Key: MG is a green population sorted from MLC-2v group 
MXG is a non-green population sorted from MLC-2v group 
UG is a green population sorted from UBC group 
UXG is a non-green population sorted from UBC group 
Fig. 3.23: Cardiac specific marker, Nkx2.5, expression in different groups of sorted 
cells. No statistical difference of Nkx2.5 expression was measured among different 
groups of sorted cells. 
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3.9.2 Gene expression of c-Tnl 
3 . 0 - | 
2 . 5 -
① 2 . 0 -
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L L 0 . 5 -
0.0-U——,——Li——,——U__,——U——,——U——, 
C T L M G M X G U G U X G 
Key: MG is a green population sorted from MLC-2v group 
MXG is a non-green population sorted from MLC-2v group 
UG is a green population sorted from UBC group 
UXG is a non-green population sorted from UBC group 
Fig. 3.24: Cardiac specific marker, c-Tnl, expression in different groups of sorted 
cells. No statistical difference of c-Tnl expression was measured among different 
groups of sorted cells. 
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3.9.3 Gene expression of c-TnT 
3 . 0 -
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Key: MG is a green population sorted from MLC-2v group 
MXG is a non-green population sorted from MLC-2v group 
UG is a green population sorted from UBC group 
UXG is a non-green population sorted from UBC group 
Fig. 3.25: Cardiac specific marker, c-TnT，expression in different groups of sorted 
cells. Statistically higher expression of c-TnT was measured in non-green population 
sorted from differentiated hESCs transduced with LV-Duet011-MLC-2v (*p<0.05 vs 
control). 
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Key: MG is a green population sorted from MLC-2v group 
MXG is a non-green population sorted from MLC-2v group 
UG is a green population sorted from UBC group 
UXG is a non-green population sorted from UBC group 
Fig. 3.26: Cardiac specific marker, MLC-2v, expression in different groups of sorted 
cells. Statistically lower MLC-2v expression was noted in both green and non-green 
populations sorted from differentiated hESCs transduced with LV-DuetOll (*p<0.05 
vs control). 
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Chapter 4 
The study of cytokines' effect on mESC differentiation 
4.1 mESC culture 
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Fig.4.1: 丄 ne appearance oi a neaimy unaiiiereniiated mESC colony with a sharp 




Fig.4.2: A closer look at a mESC colony growing on MEF feeder layer. 
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4.2 The effect of cytokines on the differentiation of mESCs 
Starting with healthy mESCs as shown in Fig. 4.1 and 4.2, differentiation of mESCs 
was performed by the hanging drops method as shown in Fig. 4.3. 
On differentiation day 2, 50 hanging drops were washed into a 100mm petri dish for 
each control or treatment group. EBs were then allowed to grow in suspension from 
differentiation days 2 to 6. During this suspension period, different concentrations of 
reconstituted cytokines were added daily at 1, 3 and 10 ratio with the cytokine levels 
during MI in r a n g e . O n differentiation day 7, 24 EBs in suspension of each control 
or treatment group were chosen and attached onto one 24-well plate until 
differentiation day 7+21. Percentages of beating EBs were recorded; both curves for 
beating at specific time point and cumulative beating curves were plotted as Fig.4.4 to 
Fig.4.15. There was no significant difference of percentage of beating EBs accounted 
between control and different treatment groups. Beating EBs were then collected at 
differentiation day 7+21 for cardiac specific gene expression and protein abundance 
analysis. Cytokines' effect on cardiac specific genes' expression of differentiated 
mESCs at mRNA and protein levels were compared and summarized in Table 4.64. 
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Undifferentiated mESC cullyre 
I 1 
i 
Formation of hanging drops ( - 8 0 0 ceils/drop) on 
the lids of p«tri dishes f i l led wi th PBS 
W l i l U W l i U M l S ] DayO 
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i 




EB suspension culture 
I 1 
» • • I Day 2-6 
I 
Attafchment of EBs onto 24-weff ptstes 
f — — -I 
Day 7+x 
• 蠱 • • 急 急 蟲 • • • 
Fig. 4.3: Hanging drops method for differentiation of mESCs, image adopted and 
modified from West JA, 2006 ^^ ^ 
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4.2.1 Beating curves of mESCs treated with different concentrations of cytokines 
at differentiation day 2 to 6 before attachment. 
( / ) ① 
100- — o — Cont ro l 
O T T / 9 IL-1 a 1ng /mL 
！: f 
容 1 
~I 1 1 1 1 
0 5 10 15 20 
Day of Dif ferentiat ion (Day7+x) 
Fig.4.4: Beating curves of IL-1 a treated differentiated mESCs compared to control. 
EBs started to beat at differentiation day 7+1 and reached a maximum at around day 
7+7. No significant difference of percentage of beating EBs was noted among control 
and different treated groups. 
•蜜 100 "I . . . ..o-o-o-o 
| e o ： _ _ _ 
1 6。： m 
① 40- i l 
g M" 
5 f ^ Contro l 
g 2 0 - ^ t IL-1 a 1ng /mL 
£1 JV IL-1 a 3ng /mL 
^ 0 - i ~ ^ I L - 1 a 10ng /mL 
^ —I 1 1 1 1 
0 5 10 15 20 
Day of Differentiation (Day7+x) 
Fig.4.5: Cumulative beating curves of IL-1 a treated differentiated mESCs compared 
to control. All groups reached percentage of beating EBs above 80%. 
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(/) — o — Cont ro l 
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I:: 1 % , 
I ： f丨 丨辑 
^ ~I 1 1 1 1 — 
0 5 10 15 20 
Day of Differentiat ion (Day7+x) 
Fig.4.6: Beating curves of IL-ip treated differentiated mESCs compared to control. 
EBs started to beat at differentiation day 7+1 and reached a maximum at around day 
7+6. No significant difference of percentage of beating EBs was noted among control 
and different treated groups. 
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O 0- i 
^ -1 1 1 1 1 
0 5 10 15 20 
Day of Differentiation (Day7+x) 
Fig.4.7: Cumulative beating curves of IL-lp treated differentiated mESCs compared 
to control. The percentage of beating EBs surpassed 80% in all groups. 
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Control 
0 IL-6 0.5ng/ml 
i g 100- - -A^ I L - 6 1.5ng/ml 
O IL-6 5ng/ml 
i： 
O 0- • • 
^ 1 ‘ 1 ‘ 1 ‘ 1 ‘ 1 ‘ 1 
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Day of Dif ferentiat ion (Day7+x) 
Fig.4.8: Beating curves of IL-6 treated differentiated mESCs compared to control. 
EBs started to beat at differentiation day 7+1 and reached a maximum at around day 
7+6. No significant difference of percentage of beating EBs was noted among control 
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Fig.4.9: Cumulative beating curves of IL-6 treated differentiated mESCs compared to 
control. The percentage of beating EBs surpassed 95% in all groups. 
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Fig.4.10: Beating curves of IL-10 treated differentiated mESCs compared to 
control. EBs started to beat at differentiation day 7+1 and reached a maximum at 
around day 7+7. No significant difference of percentage of beating EBs was noted 
among control and different treated groups. 
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Fig.4.11: Cumulative beating curves of IL-10 treated differentiated mESCs compared 
to control. The percentage of beating EBs surpassed 90% in all groups. 
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Fig.4.12: Beating curves of IL-18 treated differentiated mESCs compared to control. 
EBs started to beat at differentiation day 7+1 and reached a maximum at around day 
7+5. No significant difference of percentage of beating EBs was noted among control 
and different treated groups. 
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Fig.4.13: Cumulative beating curves of IL-18 treated differentiated mESCs compared 
to control. All groups reached percentage of beating EBs of 100% except for 
concentration at 0.3ng/ ml, 98.6% was obtained. 
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Fig.4.14: Beating curves of TNF-a treated differentiated mESCs compared to control. 
EBs started to beat at differentiation day 7+1 and reached a maximum at around day 
7+5. No significant difference of percentage of beating EBs was noted among control 
and different treated groups. 
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Fig.4.15: Cumulative beating curves of TNF-a treated differentiated mESCs 
compared to control. The percentage of beating EBs surpassed 90% in all groups 
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4.2.2 qPCR to determine the cytokines' effect on the differentiation of mESCs 
At differentiation day 7+21, EBs in 24-well plates were collected and around 8 EBs 
of each control or treatment group were taken for RNA extraction followed by reverse 
transcription of RNA to cDNA. After the confirmation of cDNA quality by PCR 
amplification of GAPDH, cDNA was subjected to qPCR with primers show in Table 
6 to check for the cardiac genes expression among different treatment groups 
compared to control group as shown in Fig.4.16 to Fig.4.45. Number of observations 
were more than or equal to four. 
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4.2.2.1 The effect of IL-la on the expression of cardiac specific genes 
According to the data obtained, IL-la treatment at lOng/ml increased MLC-2a 
expression by 2.23 folds as shown in Fig.4.19. Treatment with IL-la showed a trend 
in increased expressions of c-actin, c-Tnl and c-TnT as shown in Fig. 4.16 to Fig. 
4.18 respectively, though there was no statistical significance. However, a-MHC level 
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Fig. 4.16: Gene expression of c-actin after treatment with IL-la at different 
concentrations compared to control. 
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Fig. 4.17: Gene expression of c-Tnl after treatment with IL-la at different 
concentrations compared to control. 
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Fig. 4.18: Gene expression of c-TnT after treatment with IL-la at different 
concentrations compared to control. 
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Fig. 4.19: Gene expression of MLC-2a after treatment with IL-1 a at different 
concentrations compared to control (* p <0.05 vs control) 
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Fig. 4.20: Gene expression of a-MHC after treatment with IL-1 a at different 
concentrations compared to control. 
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4.2.2.2 The effect of IL-lp on the expression of cardiac specific genes 
For IL-lp treatment, concentration at 0.3ng/ml significantly decreased c-actin and 
C-TnT expressions as shown in Fig.4.21 and Fig.4.23 respectively. Expressions of 
c-Tnl, MLC-2a and a-MHC were increased slightly but insignificantly by the IL-ip 
treatment as shown in Fig. 4.22，Fig. 4.24 and Fig. 4.25 respectively. 
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Fig.4.21: Gene expression of c-actin after treatment with IL-lp at different 
concentrations compared to control (** p <0.01 vs control). 
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Fig.4.22: Gene expression of c-Tnl after treatment with IL-lp at different 
concentrations compared to control. 
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Fig.4.23: Gene expression of c-TnT after treatment with IL-ip at different 
concentrations compared to control (*p <0.05 vs control). 
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Fig.4.24: Gene expression of MLC-2a after treatment with IL-lp at different 
concentrations compared to control. 
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Fig.4.25: Gene expression of a-MHC after treatment with IL-lp at different 
concentrations compared to control. 
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4.2.2.3 The effect of IL-6 on the expression of cardiac specific genes 
When differentiating mESCs were treated with 0.5ng/ml IL-6, c-actin and MLC2a 
expressions decreased to 0.26 and 0.31 of the control level respectively as shown in 
Fig.4.26 and Fig. 4.29. Moreover, IL-6 at concentration 1.5ng/ml decreased c-actin, 
C-TnT and MLC-2a expressions to 0.18，0.69 and 0.62 of the control level as shown 
in Fig.4.26, Fig. 4.28 and Fig.4.29 respectively. However, the expressions of c-Tnl 
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Fig.4.26: Gene expression of c-actin after treatment with IL-6 at different 
concentrations compared to control (**p <0.01, ***p<0.001 vs control). 
1 0 1 
Chapter 4 -— Results (Part II) 







1 . 0 -
I 
0.5-
o - o U _ , U ^ , ^ L J _ , _ _ U _ _ _ , 
CTL 0 .5 1.5 5 
Concentration (ng/ml) 
Fig.4.27: Gene expression of c-Tnl after treatment with IL-6 at different 
concentrations compared to control. 
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Fig.4.28: Gene expression of c-TnT after treatment with IL-6 at different 
concentrations compared to control (*p <0.05 vs control). 
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Fig.4.29: Gene expression of MLC-2a after treatment with IL-6 at different 
concentrations compared to control (*p<0.05, **p <0.01 vs control). 
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Fig.4.30: Gene expression of a-MHC after treatment with IL-6 at different 
concentrations compared to control. 
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4.2.2.4 The effect of IL-10 on the expression of cardiac specific genes 
3ng/ml IL-10 increased c-actin and c-TnT expressions to 4.47 and 3.20 folds of the 
control level as shown in Fig.4.31 and Fig.4.33. IL-10 treatment showed a trend of 
increased expressions of c-Tnl and a-MHC as shown in Fig. 4.32 and Fig. 4.35 
respectively, though there was no statistical significance. According to Fig.4.34 the 
MLC-2a level was unaffected by IL-10 treatment. 
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Fig. 4.31: Gene expression of c-actin after treatment with IL-10 at different 
concentrations compared to control (*p <0.05 vs control). 
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Fig.4.32: Gene expression of c-Tnl after treatment with IL-10 at different 
concentrations compared to control. 
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Fig.4.33: Gene expression of c-TnT after treatment with IL-10 at different 
concentrations compared to control (*p <0.05 vs control). 
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Fig.4.34: Gene expression of MLC-2a after treatment with IL-10 at different 
concentrations compared to control (*p <0.05, **p<0.01 vs control). 
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Fig.4.35: Gene expression of a-MHC after treatment with IL-10 at different 
concentrations compared to control. 
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4.2.2.5 The effect of IL-18 on the expression of cardiac specific genes 
IL-18 treatments at 3ng/ml decreased MLC-2a expression to 0.44 of the control level 
as shown in Fig.4.39. Expressions of c-actin and a-MHC were unaffected as shown in 
Fig. 4.36 and Fig.4.40 respectively. Though there was no statistical significance, there 
was also a trend of increased expression of c-Tnl in IL-18 treatment as shown in Fig. 
4.37. 
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Fig.4.36: Gene expression of c-actin after treatment with IL-18 at different 
concentrations compared to control. 
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Fig.4.37: Gene expression of c-Tnl after treatment with IL-18 at different 
concentrations compared to control. 
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Fig.4.38: Gene expression of c-TnT after treatment with IL-18 at different 
concentrations compared to control. 
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Fig.4.39: Gene expression of MLC-2a after treatment with IL-18 at different 
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Fig.4.40: Gene expression of a-MHC after treatment with IL-18 at different 
concentrations compared to control. 
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4.2.2.6 The effect of TNF-a on the expression of cardiac specific genes 
TNF-a treatment at 0.09ng/ml reduced gene expression of MLC-2a to 0.46 of the 
control level as shown in Fig. 4.44 and at 0.3ng/ml, TNF-a decreased a-MHC level to 
0.39 of the control level as shown in Fig.4.45. Besides, the expressions of c-actin and 
C-TnT were unaffected in TNF-a treatment as shown in Fig. 4.41 and Fig. 4.43 
respectively. Though there was no statistical significance, there was also a trend of 
increased expression of c-Tnl in TNF-a treatment as shown in Fig. 4.42. 
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Fig.4.41: Gene expression of c-actin after treatment with TNF-a at different 
concentrations compared to control. 
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Fig.4.42: Gene expression of c-Tnl after treatment with TNF-a at different 
concentrations compared to control. 
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Fig.4.43: Gene expression of c-TnT after treatment with TNF-a at different 
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Fig.4.44: Gene expression of MLC-2a after treatment with TNF-a at different 
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Fig.4.45: Gene expression of a-MHC after treatment with TNF-a at different 
concentrations compared to control (*p <0.05 vs control). 
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4.2.3 Western blot analysis of the cytokines' effect on the differentiation of 
mESCs 
At differentiation day 7+21, EBs in 24-well plates were collected and around 8 EBs 
of each control or treatment group were taken for protein extraction with RIPA buffer 
with phosphatase and proteinase inhibitors. Protein concentrations were measured by 
Bradford Assay and 100|Lig of each control or treatment group was used for western 
blot in order to compare the relative abundance of cardiac specific proteins among 
control and different treatment groups as shown in Fig.4.46 to Fig.4.63. Antibodies 
against cardiac specific proteins, a-MHC, a-actinin, c-actin, and c-TnT were used in 
conditions shown in Table 8 and 9. Number of observations were more than or equal 
to four. 
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4.2.3.1 The effect of IL-la on the abundance of cardiac specific proteins 
IL-la treatment at 1 ng/ml decreased the protein level of c-actin to 0.50 of the control 
level as shown in Fig. 4.48. Protein expression of a-actinin was decreased by IL-la 
treatment at 3ng/ml to 0.60 of the control level as shown in Fig. 4.47. However, 
a-MHC protein level was unaffected by IL-la treatment as shown in Fig. 4.46. 
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Fig.4.46: Protein abundance of a-MHC after treatment with IL-la at different 
concentrations compared to control. Significant decrease of a-MHC abundance was 
observed after treatment at lOng/ml. 
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Fig.4.47: Protein abundance of a-actinin after treatment with IL-la at different 
concentrations compared to control. Significant decrease of a-actinin was noted after 
treatment at concentrations of 3ng/ml and lOng/ml (*p<0.05 vs control). 
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Fig.4.48: Protein abundance of c-actin after treatment with IL-la at different 
concentrations compared to control (**p <0.01 vs control). 
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4.2.3.2 The effect of IL-lp on the abundance of cardiac specific proteins 
IL-lp at 3 ng/ml increased a-MHC abundance to 1.40 of the control level as shown in 
Fig. 4.49. Expressions of a-actinin and c-actin were unaffected after IL-ip treatment 
as shown in Fig. 4.50 and Fig. 4.51 respectively. 
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Fig.4.49: Protein abundance of a-MHC after treatment with IL-ip at different 
concentrations compared to control (*p <0.05 vs control). 
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Fig.4.50: Protein abundance of a-actinin after treatment with IL-1(3 at different 
concentrations compared to control. 
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Fig.4.51: Protein abundance of c-actin after treatment with IL-ip at different 
concentrations compared to control. 
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4.2.3.3 The effect of IL-6 on the abundance of cardiac specific proteins 
Expression of a-MHC, a-actinin and c-actin were unaffected by IL-6 treatment as 
shown in Fig. 4.52 to Fig. 4.54 respectively. 
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Fig.4.52: Protein abundance of a-MHC after treatment with IL-6 at different 
concentrations compared to control. 
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Fig.4.53: Protein abundance of a-actinin after treatment with IL-6 at different 
concentrations compared to control. 
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Fig.4.54: Protein abundance of c-actin after treatment with IL-6 at different 
concentrations compared to control. 
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4.2.3.4 The effect of IL-10 on the abundance of cardiac specific proteins 
Expression of a-MHC was enhanced to 2.40 folds of the control level upon treatment 
with lOng/ml IL-10 as shown in Fig. 4.55. However, a-actinin and c-actin levels were 
unaffected by IL-10 treatment as shown in Fig. 4.59. 
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Fig.4.55: Protein abundance of a-MHC after treatment with IL-10 at different 
concentrations compared to control (*p <0.05 vs control). 
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Fig.4.56: Protein abundance of a-actinin after treatment with IL-10 at different 
concentrations compared to control. 
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Fig.4.57: Protein abundance of c-actin after treatment with IL-10 at different 
concentrations compared to control. 
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4.2.3.5 The effect of IL-18 on the abundance of cardiac specific proteins 
0.3ng/ml IL-18 increased the protein abundance of all three cardiac specific proteins, 
a-MHC, a-actinin and c-actin to 1.59, 3.12 and 2.05 folds of the control level as 
shown in Fig. 4.58 to Fig. 4.60. Expression of c-actin also increased by 3ng/ml IL-18 
to 2.27 folds of the control level as shown in Fig. 4.60. 
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Fig.4.58: Protein abundance of a-MHC after treatment with IL-18 at different 
concentrations compared to control (*p <0.05 vs control). 
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Fig.4.59: Protein abundance of a-actinin after treatment with IL-18 at different 
concentrations compared to control (**p <0.01 vs control). 
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Fig.4.60: Protein abundance of c-actin after treatment with IL-18 at different 
concentrations compared to control. Significant increase of c-actin abundance was 
observed in treatment at 3ng/ml (*p <0.05 vs control). 
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4.2.3.6 The effect of TNF-a on the abundance of cardiac specific proteins 
Expressions of a-MHC and a-actinin were unaffected by the TNF-a treatment as 
shown in Fig. 4.61 and Fig. 4.62; whereas the protein level of c-actin was increased to 
1.74 and 1.33 of the control level with 0.03ng/ml and 0.3ng/ml TNF-a respectively as 
shown in Fig. 4.63. 
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Fig.4.61: Protein abundance of a-MHC after treatment with TNF-a at different 
concentrations compared to control. 
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Fig.4.62: Protein abundance of a-actinin after treatment with TNF-a at different 
concentrations compared to control. 
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Fig.4.63: Protein abundance of c-actin after treatment with TNF-a at different 
concentrations compared to control (*p <0.05 vs control). 



















































































































































































































































































































































Chapter 5 - Discussion 
Chapter 5 
Discussion 
5.1 Purification of cardiomyocytes derived from differentiated hESCs 
The aim of this part of the project was to establish a transgenic hESC line that 
can allow identification and purification of cardiomyocytes derived from 
differentiated hESCs. The experimental principle is based on the use of a cardiac 
specific promoter, MLC-2v, to drive the expression of a selectable reporter gene, GFP, 
for recognition. 
This genetic method of inserting cardiac specific promoter construct for cell 
identification was used instead of the convenient cell sorting method by 
cell-type-specific membrane markers because cardiomyocytes are cells without 
specific membrane markers. Therefore, a GFP reporter gene driven by a cardiac 
specific promoter was transduced into the hESCs by lentiviruses while hESCs are 
resistant to common gene manipulation methods. After differentiation, only 
cardiomyocytes with appropriate transcriptional factors may bind to the MLC-2v 
promoter and transcribe the GFP downstream. Indirectly, cardiomyocytes were then 
labeled with green fluorescent signal. 
The use of tissue-specific promoters for selection of specific cell lineages was 
performed in mESC model and successfully identified pancreatic beta cels】。?， 
neuronsi°8，109 and cardiomyocytes.u。，� Some groups also utilized this strategy for 
the selection of early cardiac precursor cells and subpopulations of cardiomyocytes 
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like atrial/12 ventricular^^^ and pacemaker c e l l s . H o w e v e r , the first study using 
similar strategy in purifying hESC-derived cardiomyocytes was only reported last 
3 2 
year. 
The group used the same MLC-2v promoter, as what have been done in this 
study. It was because we both noted the robust expression of this gene in 
cardiomyocytes derived from in vitro differentiation of hESCs.24 A 560bp fragment of 
the MLC-2v promoter was used by that group while we used the whole sequence of 
the MLC-2v promoter. 
Despite the generation of GFP signal by cardiac specific promoter for 
recognition, in the same vector, the expression of a hygromycin resistant gene, hygR, 
was also driven under a constitutive promoter PGK. This allowed positive clones with 
transgene incorporated to be selected before large scale propagation. In contrast, the 
reported method for this selection was done by the creation of single-cell transgenic 
hESC clones.32 
The selection process with hygromycin was performed in feeder free 
system employing mTeSR medium with Matrigel. It was because the initial trial 
process on normal MEF feeder layer indicated that dying of MEFs has deviated the 
determination of antibiotic dosage to be used. Hence, feeder free system was 
employed specifically for this selection process. Nonetheless, considered the change 
of cell morphology in feeder free system as widely reported by other groups, the 
pluripotency of hESCs in feeder free system was checked. Immunostaining results 
indicated that cells expressed undifferentiated markers alkaline phosphatase and 
SSEA-4 robustly but not differentiation marker SSEA-1 in feeder-free system. This 
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implied that cells were well-kept in undifferentiated state. In addition, when hESCs 
were transferred back onto MEF after selection, the morphology of hESCs changed 
back to normal. Moreover, when the cells were subjected to differentiation afterward, 
the beating curves proved that transgenic operation and antibiotic selection did not 
have any negative impact on the cardiac differentiation potential of hESCs. For 
hESCs transduced with DuetOl l-MLC2v, average percentage of beating EBs reached 
30.7%. For the positive hESC control cell line transduced with DuetOl 1 vector, an 
average of 25.3% beating EBs were obtained versus control also got 22.9 % of 
beating EBs. 
The difference in the efficiency of cardiomyocyte differentiation may reflect 
differences in culture conditions of the undifferentiated hESCs, methods used for the 
dissociation of hESCs to generate EBs, the length of EB suspension culture, and/or 
the quality of serum used for d i f f e r e n t i a t i o n . "4，n5 por these reasons, same method for 
hESCs dissociation, same length of EBs suspension culture and same lot of serum 
were used in this project to minimize the variation in differentiation. 
At differentiation day 7+30, beating EBs were dissociated enzymatically with 
collagenase B into single cells and subjected to FACS. The green population that 
could be sorted from the differentiated hESCs transduced with DuetOl l-MLC2v was 
only around 1%. It is not a surprising finding because previous studies also reported 
that only a small proportion of differentiation derivatives of hESCs are 
cardiomyocytes. "6 
In order to verify whether the sorted green population is cardiomyocytes, 
RNA was extracted from the sorted cells and reverse transcribed into cDNA for 
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qPCR. Gene expression of four cardiac markers, including Nkx2.5, c-Tnl, c-TnT and 
MLC-2v, were compared among control group, green and non-green populations 
from differentiated hESCs transduced with DuetO 11-MLC2v or DuetOll. 
Diverged from our expectation, the targeted green population sorted from the 
MLC-2v group did not show any up-regulation of cardiac specific markers compared 
to non-green population and control group. Throughout the experiment, the progress 
was monitored tightly; first, the positive reporter line transduced with UBC-GFP 
vector showed robust GFP expression since the multiple transductions have been 
completed; and second, some GFP signals could be observed in differentiated hESCs 
transduced with MLC-2v-GFP. However, FACS-sorted green cells from the 
differentiation derivatives of MLC-2v line were not shown to be enriched with 
cardiomyocytes as determined by cardiac-gene expression at mRNA level. There can 
be several reasons that can account for the present results. First, differentiating EBs 
were needed to be digested with collagenase B into single cells and filtered through 
cell sieve before subjected to FACS; since differentiating EBs have extensive 
extracellular matrix, it was technically challenging to fully digest EBs into single 
cells with minimal destruction to the cells. Therefore, we cannot exclude the 
possibility that there are some cell clusters present even after collagenase B treatment 
and those cell clusters may have been filtered out and thereby were not subjected to 
FACS. Those cell clusters may contain cardiomyocytes which are known to express 
extracellular matrix robustly.^^^ This may explain the minimal green populations that 
were obtained. Also, setting of the cell population gates during FACS could not be 
done easily. It was because the differentiated hESCs were presented as a 
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heterogenous cell population, the cells were quite scattered on the FSC versus SSC 
plot (please refer to the result section for details). It was technically impossible to 
define a FITC-positive region without FITC-negative control cells. This might in turn 
be due to the fact that MLC-2v promoter is not a strong promoter as indicated in 
mouse studies. 113，Although the region with the least amount of FITC-negative 
cells and most FITC-positve cells was gated, only minimal percentage (around 1%) of 
green population was observed and sorted in target hESC line transduced with 
MLC-2V-GFP. 
Compared to the reported study using similar strategy in purifying 
hESC-derived cardiomyocytes, they also got MLC-2v and a-MHC expression in 
non-GFP population sorted from differentiated hESCs transduced with MLC-2v-GFP 
vector. The difference is that they had shown a stronger expression of cardiac 
markers in the GFP-sorted population compared to the non-GFP population. It is 
believed that when the total cell number of differentiated hESCs can be increased for 
FACS, there may be a better chance to allow one to identify a clearer GFP population 
and the chance of successful purification of hESC-CMs can be increased. 
On the other hand, one possible positive control that can be done in the future 
to ensure there is no problem with the target promoter construct would be to 
transduce a cardiomyoblast cell line to make sure that there is expression of the green 
fluorescent protein. Besides, quantitative PCR using primers to detect GFP expression 
in the sorted green population of cells may also confirm the success of transduction. 
For the positive reporter line hESCs transduced with UBC-GFP, it was not 
expected there is any significant difference of cardiac specific gene expression 
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between the green and non-green populations. It is because UBC is an ubiquitous 
promoter and the percentage of green population can only reflect the transduction and 
selection efficiency without providing any information for cardiac differentiation. 
However, a statistical significant down-regulation of MLC-2v expression was 
measured in both green and non-green populations when compared with that of 
control groups. This showed that the transduction of UBC promoter may 
down-regulate the expression of ventricular specific gene. Nevertheless, further 
experimental evaluations are needed to confirm the observed phenomenon and the 
possible reason(s) behind. 
The ability to identify and select for specific cell types by using tissue-specific 
promoters may have important research and clinical applications. In developmental 
biology, this allows the labeling and subsequent studies on early cardiac precursor 
cells that are difficult to be recognized due to the lack of cross-striation and 
spontaneous beating. The use of early expressed cardiac promoter such as Nkx2.5 
may allow us to gain insights into the mechanisms of cardiac differentiation and 
functional maturation. 
On the other hand, this labeling technique for hESC-CMs enables robust 
quantitation of as well as enrichment/purification of cardiac cells derived from 
differentiated hESCs. In contrast, the use of percoll gradient��，n9 qj. supplement of 
•J Q 
activin A and BMP4 in differentiation culture can only allow enrichment of cardiac 
cells. The transgenic cell line established may even acts as a reference in studies 
examining the effects of different interventions on cardiomyocyte yield. 
Most importantly, the hESC-CMs purified by this method may be used in 
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studies of myocardial cell replacement therapy. In fact, there are already many 
encouraging studies reporting the restoration of cardiac functions by the 
transplantation of mESC-CMs or hESC-CMs into myocardial infarcted heart of rat or 
other small animals like guinea pigs”，45,120-122 Therefore, if the transgenic hESC 
lines that allow identification and purification of cardiomyocytes derived from 
differentiated hESCs can be made in this project, this will be a great advancement in 
application of ESC replacement therapy. It is beacause the relatively pure population 
of cardiomyocytes generated can get rid of non-cardiomyocyte cell derivatives and 
any remaining pluripotent stem cells that might still proliferate and possess the risk of 
teratoma formation.34 However, there are still lots of issues need to be addressed for 
future therapeutic usage. Issues include the survival and integration of injected cells 
into the host myocardium, the immune response that likely may encounter and the 
functional coupling of grafted cells with the host heart tissue. Nevertheless, the 
purified cells may provide the basic material for all these further studies to be carried 
out. 
Recently, different studies had demonstrated retrovirus-mediated transfection 
with four transcription factors (Oct4, Sox2, Klf4 and c-Myc), which are highly 
expressed in ESCs, into mouse fibroblasts and has resulted in generation of induced 
pluripotent stem (iPS) cells. When mouse iPS cells were injected into mouse 
blastocysts, they contributed to all tissue types in adult mice, including sperm and 
o o c y t e . 124-126 Distinct from previous experience that it took 17 years of research to 
isolate hESCs after the success of mESCs isolation, the first report on transformation 
of human fibroblasts into a pluripotent state that resembles hESCs was released one 
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year after the success in mouse fibroblasts. '^^The group which derived mouse iPS 
cells used Oct4, Sox2, c-Myc and Klf4 (SY4) to reprogram human fibroblasts to iPS 
cells, 127 while the group which pioneered the isolation of hESCs used Oct4, Sox2, 
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Nanog and Lin28 (JT4). Researchers even worked hard to improve the efficiency 
of generating iPS cells from human adult as well as fetal fibroblasts by supplementing 
an additional gene or bioactive m o l e c u l e s ? 
Regarding to the above mentioned breakthrough in iPS cell research, one 
may oppose the use of hESCs for transplantation therapies while iPS cells can be 
patient-specific. However, the true story is that iPS cell research should be conducted 
hand in hand with hESC research. It is because iPS cell research has just begun and 
there are still lots of concerns like tumorigenicity and safety for their use in cell 
replacement therapies. One of the pluripotency-inducing transcription factors, c-Myc, 
seemed to contribute to tumor f o r m a t i o n a n d the retroviruses used to insert the 
pluripotency-inducing factors might themselves lead to cancer or deleterious 
mutations. 129 On the other hand, hESCs are currently available and much better 
studied. 
Secondly, the present hESCs derived from embryos represent the only 
pluripotent cells that are genetically unmodified. Hence, they should be used as 
important controls to investigate the safety and abilities of human iPS cells in any 
cases. 
Thirdly, there are invaluable research significances of natural hESCs that 
cannot be substitute by reprogrammed skin cells. For instance, the in vitro 
differentiation of hESCs may acts as a unique experimental system to study early 
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stages of human development. 
Taken together, if the transgenic hESC line that can allow purification of 
cardiomyocytes can be made eventually, there may have important implications for 
several cardiovascular research avenues, including basic developmental studies, 
pharmacological and physiological studies, cell therapy and tissue engineering. 
Moreover, the transgenic technique used to identify and purify hESC-CMs may allow 
high-throughput quantitation of cardiomyocytes derived from differentiaed hESCs. 
When there are suitable tissue-restrictive promoters available, the transgenic selection 
techniques applied in this study may also applicable for identification and purification 
of other cell lineages derived from differentiated hESCs. 
5.2 Study on the effect of cytokines on mESC differentiation 
In recent years, many experimental investigations in animals and several 
clinical trials had pointed out the beneficial effects of cell transplantation in cardiac 
repair after MI.^ '^ 34，36，38，120，no However, the underlying mechanisms and reasons 
behind remain anonymous. There are speculations about the stimulation of 
vasculogenesis or angiogenesis, inhibition of apoptosis, activation of endogenous 
repair mechanisms or support cells for the diseased host tissue by the injected cells.^^ 
While these effects might be mediated by the release of cytokines and growth factors, 
thereby stimulating paracrine effects, the markedly induced cytokines during MI 
might be initiators of all these signalings. Alternatively, these up-regulated cytokines 
during MI might exert some effects which enable ESCs or their differentiation 
derivatives to be suitable candidates for transplantation therapy. To start from the 
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basis, the effects of cytokines that are released during MI on mESC differentiation 
were studied. 
The inflammatory response triggered by MI can be divided into three 
overlapping phases: the inflammatory phase, the proliferative phase and the 
maturation phase. Chemokine and cytokine cascades will be activated to recruit 
leukocytes into the infarcted area during inflammatory phase. Neutrophils and 
macrophages will clear dead cells and matrix debris before the proliferative phase and 
the maturation of scar.^^ Consistent with the stages of inflammatory response, 
induction and release of the proinflammatory cytokines in mononuclear cells and 
cardiomyocytes of the ischemic myocardium are rapid. There are reports showing that 
these cytokines do play a role in cardiac repair and pathogenesis of remodeling after 
ML For instance, IL-1 signaling was proved to be essential to activate the 
inflammatory and fibrogenic pathways in healing infarct.^^^ Moreover, cells exhibited 
protective effect against inflammation and cardiac dysfunction following acute MI 
after transplantation of TNF receptor. Besides, some cytokines, including IL-6 and 
IL-la, increased the number of surviving cardiomyocytes by approximately 30% after 
10 days in vitro culture compared to non-treated controls. In addition, the rate of 
protein synthesis within cardiomyocytes was increased after 5 days.^^ 
After literature review on the types and levels of cytokines expression in mice 
after MI, six cytokines, including IL-la, IL-lp, IL-6, IL-10, IL-18 and TNF-a, were 
studies. Three concentrations of each cytokine in 1, 3 and 10 ratio with the reported 
level in-range 56-61 together with a control were studied. Cumulative and time-point 
specific beating curves of differentiating EBs treated with different cytokines were 
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obtained and on differentiation day 7+21, EBs were collected for mRNA and protein 
analysis. 
Referring to the beating curves, all sets of differentiated mESCs formed EBs 
reached percentage of beating over 80%. Among total 63 sets of cytokine treated 
mESCs formed EBs in 24-well plates, 34 sets got 100% beating. Nonetheless, the 
increase in the percentage of beating EBs in the initial phase of differentiation was 
quite sharp that normally 80% were reached at differentiated day 7+7, whilst the 
fastest case was that 100% of beating EBs was recorded on differentiation day 3 with 
IL-18 treatment. All these verified that mESC differentiation was very robust with our 
current protocol. However, whether there are enhancing effects of cytokine on mESC 
differentiation was thus difficult to be addressed by these beating curves as the 
control group also showed vigorous cardiac differentiation. In contrast, this showed 
that cytokine treatment did not decrease the percentage of beating EBs and lead to 
any delay of cardiac differentiation. Nevertheless, the beating curves could not reflect 
completely the effects of cytokines on differentiation as the EBs consist of 
heterogenous cell types and the method of counting beating EBs do not allow us to 
determine the number of cardiomyocytes presented in each EBs. The reason behind is 
that no matter there are ten cardiomyocytes or a million of cardiomyocytes in a EB 
that make that particular EB beats, one beating cluster was counted. Hence, to 
proceed further, the EBs were harvested at differentiation day 7+21 for cardiac 
markers quantitative analysis at both mRNA and protein levels to further evaluate 
whether there were enhancement or delay in cardiac differentiation after cytokine 
treatment compared to control. 
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According to the mRNA study, IL-la in concentration of lOng/ ml increased 
the expression of MLC-2a to 2.23 folds of the control level significantly while no 
significant effect was shown on the gene expression of c-Tnl，c-TnT, a-MHC and 
c-actin. No effect was observed in treatments at Ing/ ml and 3ng/ml concentrations. 
Thus, the threshold dose of IL-la to increase MLC-2a expression seems to be higher 
than 3ng/ml. Interestingly, according to the protein level analysis, lower concentration 
of IL-la at 1 ng/ml and 3ng/ml significantly lowered the protein abundance of c-actin 
and a-actinin to 0.50 and 0.60 of the control level respectively. Unfortunately, there is 
no good anti-MLC-2a antibody available to allow us to investigate the expression of 
MLC-2a at protein level. It may be possible that IL-la treatment directs cardiac 
differentiation preferentially to atrial differentiation (in contrast to ventricular 
differentiation) while decreases cardiac differentiation in general. Further 
investigation is necessary to explore this possibility. 
For IL-6 treated mESCs, qPCR data showed significantly lowered expression 
of c-actin, c-TnT and MLC-2a to 0.26, 0.69 and 0.62 of the control level respectively 
at concentration 1.5ng/ ml. Even at 0.5ng/ml, IL-6 treatment down-regulated c-actin 
and MLC-2a expression. However, protein level investigation showed no significant 
result. Similar phenomenon was observed when mESCs were treated with IL-lp 
during differentiation. It is speculated that this may be due to a loss of stability in 
predominance of mRNAs after treatment of cytokines as shown in a genome-wide 
study. A cytokine-associated change of mRNA decay was measured in this 
study. 133According to the study, among the 648 hepatic mRNAs whose abundance 
were altered under proinflammatory cytokine challenge, myosin regulatory light 
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chain was one of the genes that was found to be unstable 16 hours post cytokine 
treatment. 
In fact, there are also reports showing that the protein abundance and mRNA 
expression may not necessarily be c o r r e l a t e d ? 34 There can be presumably three 
reasons for the poor correlations between mRNA expression and protein abundance. 
Firstly, the complicated and diverse post-transcriptional mechanisms involved in 
turning mRNA into protein are not yet sufficiently well studied and do not enable 
good computation of protein concentration from mRNA. Secondly, the in vivo half 
lives of proteins differ substantially. Finally, the long protocols and hence certain 
amount of error and noise in both protein and mRNA experiments limited our ability 
to get the real picture?34 
Therefore, the change in mRNA stability and the inability to correlate mRNA 
and protein abundance may be used to explain the observed decrease in mRNA level 
of and unchanged protein level of cardiac markers by cytokine treatment. Further 
study is necessary to explore this possibility. 
On the other hand, mRNA study illustrated the increased expression of c-actin 
and C-TnT genes to 4.47 and 3.20 folds of the control level when mESCs were treated 
with IL-10 at 3ng/ml. Besides, IL-10 at lOng/ml increased the protein abundance of 
a-MHC to 2.40 folds of the control level. It appears that IL-10 brought quite 
consistent up-regulation of cardiac specific genes expression. 
For the effect of TNF-a treatment on cardiac differentiation, up-regulation of 
c-actin protein abundance to 1.74 and 1.33 folds of the control level was resulted at 
0.03ng/ml and 0.3ng/ml respectively. 
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Lastly, western blot analysis showed up-regulation of the three cardiac 
specific proteins at 0.3ng/ml IL-18 treatment. C-actin abundance was also increased 
to 2.27 folds of the control level after IL-18 treatment at 3ng/ml. While interleukin-18 
is a pro-hypertrophic cytokine that acts through a Phosphatidylinositol 
3-Kinase-Phosphoinositide-dependent Kinase-1 -Akt-GATA4 signaling pathway in 
cardiomyocytes 135, the enhancement of cardiac differentiation by IL-18 treatment 
might via PISK-Akt-dependent N F - K B activation^^^ as overexpression of N F - K B is 
well known as stimulator of cardiac differentiation^ 
The present study on single cytokine effect on the differentiation of mESCs is 
a basis to illustrate the effect of pro-inflammatory cascade on mESC differentiation. 
The discrete waves of stimulation by TNF-a and IL-ip, and then IL-6, which occur in 
vivo and the combination of different pro-inflammatory cytokines at different 
inflammatory stages may be mimicked further to get more detailed information. 
Indeed, this is crucial in some cases that opposite effect of cytokine on some acute 
phase proteins may be attained when the cytokine acts in the context of other 
cytokines, like IL-lp in the presence of IL-6. 
While we added the cytokine during differentiation day 2 to 7，a period when 
early and dynamic differentiation occurred to build up the 3-D structure of EBs in 
suspension, the effect of cytokines on cardiac progenitor cells differentiation was 
studied. According to the qPCR studies, treatments of IL-lp, IL-10, IL-18 and TNF-a 
caused up-regulation in cardiac specific genes expression. This may indicate that 
cardiac progenitor cells differentiate better to cardiomyocytes in the presence of 
inflammatory cytokines 
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As a result, progenitor cells may be injected during and at the site of 
inflammation for cell replacement therapy after MI. In another way, inflammatory 
cytokines may be added additionally to favor ESCs differentiation in vitro before 
being used for cells transplantation 
While the present study only focused on the effect of cytokines on mESC 
differentiation, the effect of cytokines on mESC maturation and incorporation can be 
studied with a similar experimental design in the future for a complete picture of how 
cytokine may affect the efficacy of ESC-CM transplantation in myocardial infarcted 
hearts. Maturation and incorporation are important issues for ESC-CM transplantation 
as "embryonic-like" pre-matured cells are not electrically quiescent (i.e. generate 
spontaneous action potential even without stimulation) and therefore may lead to 
arrhythmias. In addition, there should be good communication between injected cells 
and the infarcted host cells in order to convey synchronized electrical signals. 
Otherwise, arrhythmia may occur. 
The cytokine effect on mESC maturation can be studied by adding 
reconstituted cytokine powder into EBs in suspension at differentiation day 2 to 7. 
EBs at different differentiated time points may then collect for molecular studies to 
keep track of the expression levels of maturation markers, e.g a-actinin and 
sarcomeric actin.''^^ In tissue level, the muscle structure and striation of matured 
cardiomyocyte can be observed by immunohistochemistry. 
In order to study the effect of cytokines on the incorporation of ESC-CMs into 
host hearts, the presence and quantity of gap junctions (e.g. connexin 43), and the 
transfer of electrical signals, between injected cells and host muscles can be measured. 
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The data obtained from normal hearts and that obtained from infarcted heart can be 
compared and contrasted to review the effects of cytokines released on ESC-CM 
incorporation. 
5.3 Conclusion 
The present study intended to establish a hESC line whose cardiac derivatives will 
preferentially be labeled with GFP in order to obtain a pure population of hESC-CMs 
though further verification on the labeled cells needs to be performed. On the other 
hand, cytokine effects on mESC differentiation were studied. At mRNA level, it was 
found that IL-1 a treatment increased atrial specific gene, MLC-2a, expression by 2.23 
folds at lOng/ml. IL-lp treatment significantly lowered expression of c-actin and 
c-TnT to 0.36 and 0.45 of the control level respectively at 0.3ng/ml. IL-6 treatment 
lowered c-actin and MLC-2a expressions at 0.5ng/ml. Besides, IL-6 at 1.5ng/ml 
significantly down-regulated all three cardiac specific genes' expression. IL-10 
increased c-actin and c-TnT expression to 4.47 and 3.20 folds of the control level at 
3ng/ml. For IL-18 treatment, MLC-2a expression decreased to 0.44 of the control 
level at 3ng/ml. Lastly, TNF-a treatment lowered MLC-2a and a-MHC expression at 
0.09ng/ml and 0.3ng/ml respectively. 
At protein level, IL-1 a at 1 ng/ml and 3ng/ml decreased the protein abundance of 
a-actinin and a-MHC to 0.5 and 0.6 of the control level respectively while IL-lp at 
concentration of 3ng/ml increased a-MHC abundance to 1.40 of the control level. 10 
ng/ml IL-10 increased a-MHC abundance to 2.40 folds of control level. In addition, 
IL-18 treatment at 0.3ng/ml increased all three cardiac specific proteins abundance 
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while at 3ng/ml, only c-actin abundance was up-regulated to 2.27 of the control level. 
Finally, TNF-a treatment increased c-actin abundance to 1.74 and 1.33 folds of the 
control level at 0.03ng/ml and 0.3ng/ml respectively. 
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